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OUTLINE OF THESIS 
 
This thesis details my journey as a research nurse describing the design, pre-study application 
process and performance of one of the first genotype-stratified randomised controlled studies 
in children with asthma.  
 
Background 
β2-agonist response may be affected by β2 adrenoreceptor genotype (ADRB2).  The arginine-
16 (Arg 16) variant of this gene predisposes to exacerbations in asthmatic children and young 
adults, particularly in those exposed to regular salmeterol.   There follows the presentation of 
a proof-of-principle randomised controlled trial of add-on therapy to inhaled steroids, with 
either oral montelukast or inhaled salmeterol, on children carrying the susceptible Arg-16  
genotype over a 1-year period. 
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Methods 
I have explored methodological issues of importance in the design of this complex study in 
children. I have also analysed some of the practical aspects of the ethics-related issues 
associated with the study, the response of parents and children, and how these issues were 
managed within the context of this study. 
 
Results 
Asthmatic children with the Arg-16 genotype appear to have better asthma control when 
prescribed montelukast compared to salmeterol, when added to inhaled corticosteroid, over a 
12 month period.  Sixty two asthmatic children with the Arg-16 genotype were randomised to 
receive montelukast 5/10mg once daily or salmeterol twice daily as add on therapy to inhaled 
fluticasone for 1 year.  School absences (the primary outcome) were reduced with  
montelukast compared to salmeterol: p = 0.005.  Salbutamol use was also reduced with  
montelukast compared with salmeterol: p < 0.0001, and improvements were also found in 
symptom and quality of life scores with montelukast in comparison to salmeterol.   
 
Conclusions 
Montelukast may be suitable as tailored second line controller therapy instead of salmeterol in 
asthmatic children expressing the susceptible Arg-16 genotype - moving towards a 
personalised medicine approach to management.  The study has suggested the need for larger 
studies which explore the role of genotyping in improving the care of children with asthma. 
It has also provided the opportunity to explore the issues around consenting and recruiting 
children within the context of prospective genotyping progressing to randomisation, and the 
subsequent allocation of children to specific pharmacological interventions on the basis of 
genotype. 
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SECTION 1 - INTRODUCTION 
 
Chapter 1 
 
ASTHMA IN CHILDREN 
 
Incidence in children 
The incidence of asthma in both adults and children in the UK is one of the highest 
worldwide.1 An estimated 1.1 million children are said to have asthma in the UK2, making 
asthma the most common chronic disease of childhood and one of the main reasons for 
childhood hospital admissions.3   Work in Scotland has estimated that 1 in 11 children are 
receiving treatment for asthma.4 
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The onset of asthma commonly occurs during preschool years.5  A high percentage of pre-
school children will have episodes of wheeze, cough and increased work of breathing 
associated with viral upper respiratory infection.  Studies have found that up to half of those 
children who had symptoms in the first year of their life will no longer experience such 
episodes by early school years.6  The patterns of expression of childhood asthma that persist 
into adult life have been explored and distinct asthma phenotypes (transient wheezing, non-
atopic wheezing, and atopy-associated asthma) have been identified.7  Several factors, such 
as age at presentation, gender, severity of previous wheezing episodes, co-existing atopic 
disease and family history of atopy, are associated with the development of asthma in 
childhood.8 
 
 
 
Genetic & Environmental predisposing factors for Asthma 
The exact cause of asthma is not completely understood but it is thought to result from a 
combination of genetic make up and the environment to which the individual is exposed.9,10  
Environmental factors include indoor allergens (e.g. house dust mites, pollution or pet 
dander) or outdoor allergens such as pollens, moulds, tobacco smoke and chemical irritants.  
An increasing number of genes that may be predictive of asthma have also been studied.11 
 
How does asthma affect children? 
Having asthma can restrict the ability of children to participate in everyday activities, cause 
school absences3 and affect performance at school because of night disturbances.12  In 
quality-of-life studies, children with asthma rated being well enough to attend school and 
participate in sports as important to them.12  Uncontrolled asthma and the possibility of an 
asthma attack can influence family decisions about activities such as holidays and can affect 
11 
 
 
social well-being in childhood.13  Studies have shown school attendance of children with 
asthma can be poorer, and the ability to take part in physical activities is affected in 
comparison to healthy non-asthmatic children.14  More school absence is reported due to 
asthma than any other chronic disease.  In the US up to 60% of children with asthma miss 
school annually due to respiratory symptoms.15,16  Children with obesity are at increased risk 
of developing asthma.  The reasons for this have not yet been defined but diet, reduced 
physical activity or genetic alterations that increase tendency towards both obesity and 
asthma are all said to contribute.17 
 
Pharmacological Treatments for Children’s Asthma 
There are two main types of asthma pharmacological treatments (1) reliever drugs that target 
acute airway bronchoconstriction and (2) preventer drugs used to reduce airway inflammation 
and the severity and frequency of exacerbations.  The main reliever medications, and the 
most commonly used asthma treatments, are β2 agonists e.g. salbutamol.  For moderate and 
severe persistent asthma reliever treatment is combined with inhaled corticosteroids – 
preventer drugs - to reduce the severity of airway inflammation.18   
 
National Guidelines 
The British Thoracic Society Asthma Guidelines classify treatment recommendations into 
five steps depending on the severity of the child’s asthma.18   Step I of asthma treatment is 
reliever inhaler used only as needed and step II is daily inhaled corticosteroids with reliever 
as needed.  At step III, long-acting β2-agonists are added when symptoms are inadequately 
controlled by inhaled steroids alone.18  If a combination of inhaled long-acting β2-agonist and 
inhaled steroids does not control asthma symptoms adequately, montelukast, a leukotriene 
receptor antagonist, can be added as additional therapy.  Asthma that is uncontrolled at step 
III is managed through the addition of further levels of medication such as oral theophylline 
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(step IV).  Steps IV and V of the guidelines advise increased levels of inhaled corticosteroid 
and finally the addition of daily oral corticosteroids.18 
 
Variations between Childhood and Adult Asthma 
A diagnosis of asthma can be assumed when a child presents a pattern of such respiratory 
symptoms where no alternative causative explanation can be provided.18  There are several 
issues unique to children that must be kept in mind when asthma characteristics are studied in 
paediatric age-groups.  There are important differences in the clinical features and 
pathological characteristics of asthma between children and adults.19,20  Different wheezing 
phenotypes exist in children that potentially affect children to varying degrees at different age 
groups.5  In addition, the adverse effects of asthma treatments may also vary between children 
and adults.21,22 Side effects that may not affect adults may be very important in children e.g. 
the effect of high dose inhaled corticosteroids on growth in children.18   
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Chapter 2 
 
THE PATHOLOGY OF CHILDREN’S ASTHMA 
 
This chapter briefly outlines the pathology of children’s asthma and I have aimed to relate 
this to the pharmacological effects of the main two asthma drugs used in the thesis study – 
salmeterol and montelukast. 
 
 
Pathology of Asthma Exacerbations 
The clinical symptoms of asthma - wheeze, cough, chest tightness and breathlessness occur 
as a result of chronic inflammation of the airways and acute inflammatory episodes 
(exacerbations).10  The inflammatory responses in an exacerbation, involve the action of cells 
such as mast cells, lymphocytes, eosinophils, neutrophils, macrophages and also chemical 
mediators called leukotrienes, which are produced by these cells.  
 
Inflammation of the airways and airway reactivity cause bronchospasm, mucus secretion and 
oedema of bronchial tissue.20 Airway wall epithelial cells mix with mucus to form thick plugs 
which can block the narrow diameter of a child’s airway and restrict air flow through the 
bronchioles.  
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Pathogenesis of airway obstruction in asthma 
 
 
 
 
 
Reproduced by kind permission Harmanci K (2007) 
'Montelukast: its role in the treatment of childhood asthma'  
Therapeutics and Clinical Risk Management Vol 3 Issue 5 October pp 885-892.  
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Pathology of inhaled β2 agonists in Asthma 
β2 agonists are one of the first choice medications to treat exacerbations.  Following 
inhalation, asthma drugs are deposited on the mucosal fluid lining of the airways. The target 
of β2 agonists are β2-adrenoceptors (β2ARs) in the bronchial smooth muscle.  β2ARs are 
protein receptors on the cell surfaces that signal to the interior of the cell through multiple 
mechanisms causing the cellular response to inhaled β2 agonist.   
 
Signaling cascade involved in the β2 receptor activation  
By binding to the receptor, β2 agonists such as salbutamol initiate intracellular biochemical 
events.  The process of β2 receptor activation is mediated by adenylyl cyclase stimulation and 
subsequent cyclic adenosine monophosphate (cAMP) formation. cAMP messenger activates 
protein kinase (PKA), which transfers the effects of salbutamol into the cells,  resulting in 
bronchodilation by relaxing the smooth muscles of the airways from the trachea to the 
terminal bronchioles.21 
 
Arg/Arg 16 Single Nucleotide Polymorphism of the β2 adrenergic receptor  
A number of Single Nucleotide Polymorphisms (SNP's) in the β2 adrenergic receptor gene 
have been studied.  It is believed that the polymorphic changes at position 16 have normal 
agonist binding at the receptor, but there is less interaction between the β2 receptor and β2 
agonist drugs in individuals who have this particular genetic variation.   
 
Down regulation of the β2 adrenergic receptor  
Down regulation occurs during prolonged agonist activation and is a decrease in the number 
of cell surface receptors.  The mechanisms leading to the process are highly cell dependent. 
The Arg/Arg16 polymorphism confers relative protection against down-regulation by 
endogenous catecholamines, making individuals susceptible to uncoupling and internalisaton 
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of receptors known as desensitisation followed by a decrease in receptor density and receptor 
gene expression known as down regulation.23  
 
Short acting and Long acting β2 agonists 
There are two main types of β2 agonists used in children's asthma – short acting β2 agonists 
and long acting β2 agonists (LABAs) e.g. salmeterol.   The degree of bronchodilator response 
of β2 agonists is related to the concentration of drug in the smooth muscle cells, and the extent 
of activation of the receptor by the β2-agonist.23   
 
The exact mechanisms by which salmeterol causes prolonged bronchodilation is not fully 
understood but it is thought that the drug can be stored in cell membranes in the airways and 
therefore accessible to the β2ARs for a longer period.24   In comparison the short acting β2-
agonist will diffuse more readily through the airway tissue and is dispersed quicker. 
 
Pathology of Montelukast in Children's Asthma  
Leukotrienes are key mediators of the inflammatory airway responses.  They have both 
bronchoconstrictor and inflammatory roles in the pathophysiology of chronic asthma.25 
Montelukast inhibits the leukotriene pathway and acts through a different pathway to that 
involved when the β2AR is activated.  Montelukast is known to be effective in children’s 
asthma.25 
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Chapter 3 
 
MEASURES OF ASTHMA CONTROL 
 
In this chapter measures of asthma control used in the study are discussed as outcome 
measures, showing examples of evidence to support their effectiveness in clinical trials and 
contraindications for their use in both clinical practice and research involving children. 
 
There are issues unique to children that clinicians and researchers should be mindful of when 
assessing symptoms and evaluating treatment outcomes.  Children may not recognise 
symptoms or have difficulty describing symptoms.  Parents can report symptoms but there 
may be differences between reports from children and their parents. 
 
In asthma clinical trials, objective measures such as lung function, airway inflammation and 
need for short-acting inhaled β2 agonist have traditionally been used to evaluate the effect of 
asthma interventions. Child and parent-reported outcome measures describing quality-of-life 
can also be used to provide both quantitative and qualitative data.  Outcomes commonly used 
in routine clinical practice, such as symptoms scores, frequency of periods of increased 
symptoms and peak expiratory flow rate variability are also useful as clinically significant 
end-points for evaluating the role of asthma interventions.  A brief discussion of commonly 
used outcome measure follows, with particular emphasis on the outcome measures used in 
the main thesis study. 
 
School Absence as a result of Asthma 
Absence from nursery or school due to asthma is a relevant outcome measure to evaluate 
asthma control because being able to attend school matters to children and parents.  In 
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studies, it provides a qualitative assessment of response to asthma treatment which can be 
measured retrospectively either from parent/child recall or school records.3  In clinical 
practice a record of time off school is a useful indicator of control.  Comparisons of school 
absence can be made among study groups where participants have been randomised, or where 
a comparable participant group is included.26   A study carried out in Tayside used school 
absence as an outcome indicator and showed that children prescribed inhaled salmeterol had 
more school absence in comparison to other asthma treatments.27 It could be argued that 
parent/child recall may be inaccurate but in a study where the child is closely monitored with 
a number of visits over a short period the likelihood of inaccuracy will be less.  School 
absence data can be obtained from school records but this may be of limited value if the exact 
cause of absence is not recorded.   
 
Exacerbations 
Exacerbations of asthma are defined as an acute worsening of chronic asthma requiring one 
or more of the following (1) systemic use of corticosteroids, (2) asthma-specific emergency 
department attendance or hospital admissions28 or (3) increased use of short acting β2 agonists 
as rescue inhaler.29  As a measure of control, exacerbations indicate changes in clinical status.  
However visits to emergency departments and hospital admissions are usually infrequent in 
children.  In contrast courses of prednisolone18 and β2 agonist use can be recorded as more 
frequent events over a shorter period of time.   
 
Mild clinical exacerbations in children can include increased nocturnal symptoms, 
breakthrough symptoms, and asthma-related school absences.10  These markers are observed 
more frequently over a shorter period and smaller numbers needed to observe an effect.  
Some studies have combined all these levels of exacerbations into asthma control days. 30 
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Summary of Clinical Features 
In clinical trials a summary of asthma symptoms from the child and/or parent are commonly 
used to give an index of response to treatment.31,32  During an asthma exacerbation, children 
will experience shortness of breath, cough and/or wheezing.  Between attacks, they may be 
asymptomatic or describe mild-to-moderate symptoms that could be related to exertion, or 
nocturnal awakening due to narrowing of the airways at night.  These clinical features that 
change over time altering asthma status are useful to study the course of the disease. Asthma 
symptoms in children tend to be more variable in comparison to adults.33 
 
Use of inhaled short-acting β2 agonists 
Short acting β2 agonist use has been widely used as an indicator asthma morbidity and a 
marker of asthma control in children.34,35   This can be obtained from parent/child recall 
which would rely on their ability to recognise symptoms and record frequency of use.  
Information on frequency of prescription collection could also be obtained via Primary Care.  
 
Pulmonary Function 
Measuring pulmonary function by means of spirometry is one of the more traditional asthma 
assessment methods in clinical settings.  It is easily obtainable in older children and can 
provide an objective measure of airway inflammation and pathological changes in the airway 
over time.  Spirometry measurements, such as the volume of air that can be forcibly expired 
during the first second of expiration after a maximal inspiration (FEV1), and peak expiratory 
flow rate (PEFR), the maximal flow rate achieved during forced exhalation, can effectively 
demonstrate the action of bronchodilator treatment.  
 
However, it can be more difficult to quantify the effect of a treatment using pulmonary 
function alone in children because the majority have lung function measurements within the 
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normal range limiting the potential to show benefit.26,27   Studies of asthmatic children with 
poorly controlled disease had no effect on pulmonary function following the addition of long 
acting β2 agonists.36, 37  
 
It can also be argued that pulmonary function changes may not associate with outcomes that 
are relevant to children and their families.  Changes in day to day symptoms may not be fully 
captured with pulmonary fucntion alone.  Children and their families may perceive some 
asthma symptoms as more troublesome than others and may report benefits from asthma 
treatment which cannot be explained on the basis of clinical pulmonary function.   
 
Quality-of-life related outcomes  
In contrast to physiological outcome measures used to assess asthma, the aim of quality of 
life measurement is to assess the impact asthma has on the child’s daily life and emotional 
well-being.  Increasingly, the National Institute for Health and Clinical Excellence (NICE) 
and other bodies are placing more emphasis on qualitative assessments such as the Paediatric 
Asthma Quality of Life Questionnaire, as outcome measures, to assess response to asthma 
treatment in children.38,39 
 
Quality of life tools for children with asthma measure emotions, asthma severity/symptoms, 
missed school days, activity limitations and visits to the emergency department40 and are used 
to capture the effects of treatments and asthma control as perceived by the children 
themselves.   
 
Clinical and laboratory measurements of asthma do not always correlate with each other, and 
information from patients is valuable in evaluating the asthma status. Studies in adults with 
asthma have shown only small links between clinical outcomes and how patients feel and 
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function daily.41 42  If only traditional asthma clinical end-points such pulmonary function are 
measured in clinical trials, it is possible that important patient perceived benefit to treatments 
may be missed.43,44 Thus to gain a full picture of the impact of asthma on the lives of 
sufferers, measurements of health-related quality of life should be considered. 
  
Asthma diaries 
Measuring peak flow can provide a quantitative measure of asthma, to help detect early 
changes that may require treatment or to evaluate responses to changes in therapy.  Current 
asthma guidelines recommend peak flow monitoring during exacerbations of asthma to help 
determine the severity of exacerbations.  Change from baseline in morning peak flow as 
recorded in daily diary cards can be used in research studies.45  It is important to acknowledge 
that there is a risk that children will not maintain adherence and the potential for incorrect 
readings should be recognised as a limitation to long-term peak flow monitoring.45 
 
Inflammatory Biomarkers 
Biomarkers in asthma can be defined as measurements in the laboratory associated with the 
biology or physiology of the clinical disease process in asthma.46 Inflammation plays a major 
role in the pathophysiology of asthma and mediators of airway inflammation in exhaled 
breath, urine, sputum, blood or saliva are used to monitor asthma and to evaluate response to 
interventions.47 
 
Exhaled Nitric Oxide (FeNO) 
Exhaled breath nitric oxide (FeNO) may reflect eosinophilic airway inflammation in asthma. 
There is a significant relationship between FeNO measurements and eosinophilic airway 
inflammation. In children, management based on FeNO as an end point has been associated 
with improvements in airway hyper-responsiveness, but not with clinical benefits as reflected 
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by patient-experienced outcomes, such as symptoms or the need for rescue medication.30  In 
addition, most studies have not shown a reduction in exhaled FeNO levels at step III asthma  
treatment with inhaled long-acting beta agonists in asthma.48,49 
 
Eosinophilic cationic protein (ECP) 
The status of eosinophils is known to be an indirect marker of airway inflammation in 
asthma. Total eosinophil count reflects asthmatic activity and has been shown to be useful for 
regulating steroid dosage and for early detection of exacerbations.50  A number of studies 
have indicated that the assessment of eosinophil-derived proteins in serum or urine samples 
may be useful for monitoring disease activity in asthma. The eosinophil granule proteins 
often function well as inflammatory markers when used in controlled clinical studies and are 
therefore useful research tools.  
 
Eosinophilic cationic protein (ECP) has been most frequently used as a marker of 
inflammation.  It is produced and secreted by eosinophils.50  ECP is used in clinical trials for 
monitoring disease activity.  However obtaining levels of serum ECP either from blood, or 
sputum samples is invasive for children and may be a deterrent for children to participate in a 
study. 
 
Based on this information, the research team debated whether the analysis of ECP in saliva 
may be adequate to enable clinically relevant assumptions on the status of the airways in 
patients with asthma. However, on overall analysis, it was felt that the current state of 
understanding of the relationship between salivary ECP levels and asthma symptom control is 
unclear.   
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Although there is increasing evidence to support a role for ECP and FeNO as biomarkers of 
asthma status, in this study it was felt that clinical outcome measures, such as absence from 
school, and asthma-related quality-of-life, were more likely to indicate benefit for patients, in 
comparison to ECP or FENO measurements. Thus, on balance, I conclude that a more 
relevant endpoint for comparison of disease activity in children’s asthma may be represented 
by outcomes such as school absences, other measures of asthma exacerbations, and asthma 
symptoms scores measured over a certain period of observation during the comparison of 
interventions.  Inflammatory biomarkers can reveal important information about the disease 
process, but will not capture how the patient feels and is affected by asthma on a daily basis 
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Chapter 4 
 
 
ROLE OF GENETIC VARIATION ON ASTHMA CONTROL AND SEVERITY 
 
Polymorphic variations in a number of inflammation-related genes have recently been shown 
to exert important effects on susceptibility to allergy and asthma. Such variation can also 
affect asthma clinical phenotype in childhood, thus influencing asthma severity. There has 
been major progress in this area of research over the past decade, including work that 
specifically relates to children. The body of literature is very large. However, the concept of 
genetic regulation of aspects of asthma control, through interaction with environmental 
factors such as exposure to medication, is of central importance to my thesis. Hence, this 
section, will review some specific, important examples from recent literature of the effect of 
genetic variation on asthma severity.  
 
Filaggrin gene variation and the effect of this variation on asthma control in childhood. 
Filaggrin (FLG) gene variation 
Two independent mutations in the gene (R501X and 2282del4) of the filaggrin gene (FLG) 
have been shown to strongly predispose to childhood eczema and other atopic conditions.51 
The filaggrin gene mutations are common in several white European populations, and in the 
UK, about 10% of children appear to have a skin barrier resulting from filaggrin gene 
mutations.  
 
Filaggrin  
Filaggrin is a structural protein found within the stratum granulosum cell layer of the 
epidermis, which maintains the skin barrier function.  Filaggrin helps to form a keratin 
cytoskeleton to compact cells, known as squame.  Squame is a cell barrier in the skin, 
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impermeable to chemicals, that retains water and prevents entry of antigens, allergens and 
irritants from the environment.  Absent or reduced filaggrin in children with the FLG gene 
mutations R501X and 2282del have been found to disrupt barrier formation and possibly 
permit transcutaneous antigen/allergen/ irritant transfer through the skin.52 
 
Effect of Filaggrin variation on asthma control in childhood 
The severity of disease in children with established asthma has been shown to be increased in 
children with the ‘at risk’ form of the FLG gene variation.53,54  The presence influences 
controller and reliever medication needs in asthmatic children53 and leads to a greater risk of 
asthma attacks.52  Furthermore, other markers of asthma severity in childhood, e.g. school 
absences, use of oral steroids, and frequency of hospital admissions appear to be influenced 
by variations in the FLG gene and the effect of these variations on skin barrier function.54   
This influence could be the result of differences in skin barrier function which may result in 
different patterns of allergen entry through the skin. 
 
Glutathione-S-transferase (GST) variation influences lung function in children with 
asthma  
Glutathione-S-transferase (GST) gene variation 
The most studied variants of the Glutatione-S-transferase gene are GSTM1 and GSTT1, 
present in 50% and 20% within white populations, respectively, and also a variant of GSTP1, 
which constitutes 10% of the white population.55 
 
Glutathione-S-transferase 
Glutathione S-transferases are an important family of enzymes involved in the detoxification 
processes occurring within the human body.  Polymorphic variation of the gene's synthesising 
proteins, can lead to differences in the activity of these enzymes.57 GSTM1 and GSTP1 are 
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enzymes that protect the airways from oxidative stress, which is linked to asthma 
pathogenesis.  A reduction in the activity of GSTs may lead to an impairment of the 
detoxification process in the lung and other parts of the body which could contribute to worse 
asthma.  These enzymes that contributing to local detoxification in alveoli and bronchioles 
also have an important role in the defence mechanism against tobacco smoke.   
 
Glutathione-S-transferase gene variation in children with asthma 
A number of studies have investigated the relationships between different polymorphisms of 
GST and aspects of asthma clinical phenotype in children.  Genes encoding the GSTs have 
been implicated in various aspects of immune responses in the pulmonary and cardiovascular 
systems and there are reports of a modulating effect of genetic variation in GSTs on asthma 
susceptibility.55 and that GSTM1 is associated with asthma risk in children exposed to 
tobacco smoke 
 
Smoke exposure has been linked to poorer asthma outcomes.  In GSTM1-null children of 
school age, in utero exposure to smoking is associated with an increased prevalence of early 
onset asthma, asthma with current symptoms, persistent asthma, lifetime history of wheezing, 
wheezing with exercise, wheezing requiring medication, and emergency department visits in 
the past year.56  Variation in the GSTM1 locus influences lung function in children. This 
effect was particularly important among children whose mothers smoked during pregnancy.57 
In cross sectional analysis of childhood asthma, it was observed that in utero exposure to 
maternal smoking was associated with increased risk of asthma/wheeze only among carriers 
of the GSTM1 null genotype.58  Tobacco smoke exposure was also found to exert a particular 
adverse effect on peak expiratory flow rate in teenagers with asthma carrying the common 
GSTM1 null variation.59 
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Peroxisome proliferator activated receptor – gamma (PPAR-gamma) variation and asthma 
Peroxisome proliferator activated receptor – gamma variations 
Variation in the gene synthesising the peroxisome proliferator activated receptor – gamma 
(PPAR gamma) protein represents another example of the effect of gene change on asthma 
severity in childhood.  A number of functionally important polymorphisms of the PPAR gamma 
gene, Pro12Ala, C1431T, and C-681G, are present in the population in Scotland.  
 
Peroxisome proliferator activated receptor – gamma 
PPAR gamma is a nuclear receptor, and has an anti-inflammatory role in the human body. The 
role of this protein has been particularly investigated within the context of vascular disease 60 and 
cancer62  PPAR gamma is expressed in the lung and is likely to have similar, although currently 
unexplored, roles in the lung.  
 
Peroxisome proliferator activated receptor – gamma associated with increased risk asthma 
exacerbations 
Work has shown that ProC represents an ‘at-risk’ polymorphism for asthma.61  This variant is 
commonly present and is associated with increased risk of asthma exacerbations in children.  
Specifically, the ProC genotype was associated with increased school absences and hospital 
admissions over a period of 6 months.  This paper concludes that common genetic variation at 
the PPARG locus may play an important role in modulating the long term control of asthma in 
children and young adults.62 
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Beta2  adrenoreceptor gene polymorphism may result in variability in response to asthma 
treatments 
β2 adrenoreceptor gene polymorphisms (ADRB2) 
In the human population, a number of polymorphisms of the β2 adrenergic receptor gene have 
been found, at least 3 of which result in receptors that have different properties.  Two common 
variants at amino acid positions 16 (Gly16Arg) and 27 (Gln27Glu) have been the focus of 
clinical studies in asthma.  Specifically, the polymorphism Arg/Arg-16 of the β2 adrenergic 
receptor has been linked with increased symptoms and exacerbations in children with asthma.27,63   
 
Prevalence of Arg/Arg-16 gene variation 
About 15% of children of Northern European origin are homozygous for the Arg/Arg-16 gene 
variation. Approximately 45% of the population carries one arginine and one glycine residue at 
position 16. Thus about 15 % of the population may be susceptible to the effects of differential β2 
agonist response, although it is possible that a much larger population may be partially 
affected.27,64  
 
Beta2adrenoreceptor  
Variability in response to asthma treatments can be influenced by variation in the structure of the 
receptor molecules that bind to asthma medicines. An important receptor in this context is the 
adrenergic β2 receptor that binds to two of the most common medicines used in children’s 
asthma, inhaled β2-agonists - salbutamol and salmeterol.  Inhaled β2-agonists cause dilation of 
constricted airways by binding to the β2-adrenoreceptors on airway smooth muscle. 
Naturally occurring polymorphisms in the β2 adrenoreceptor gene (ADRB2) might alter the 
function and expression of the adrenoreceptor and therefore affect response to short and long 
acting β2-agonists.64  The β2-adrenergic receptor has been found to have significant genetic 
variability in its structure resulting in differences in the way the receptor functions.64 
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Beta2 adrenoreceptor gene variability in response to asthma treatments 
The hypothesis that this variation may lead to differences in treatment response in children’s 
asthma has been tested.27,63  Past studies have associated the Arg/Arg-16 gene variation, with a 
reduced response to short-acting β2-agonists65, as well as perhaps to long-acting beta2-agonists.66 
This has led to concerns that the use of combined inhaled corticosteroid (ICS) and long-acting β2 
agonist medications, would result in poor clinical outcomes in patients with polymorphisms of 
this gene. Observational studies in Scottish children with asthma have consistently shown a role 
for β2 adrenoreceptor variation in β2 agonist response.27,63  Hence, there is a need to study the role 
of this receptor on therapeutic response in Scottish children with asthma 
 
Conclusion 
I have reviewed a number of studies that have identified individual candidate gene variants that 
are associated with a more severe asthma phenotype. However, in most clinical situations, such 
variants have limited use in the prediction of disease severity, since most of them confer a 
relatively small risk. In other disease areas, such as multiple sclerosis, prostate cancer and type II 
diabetes, combinations of individual gene variants have a cumulative effect, conferring larger 
associations with susceptibility to these diseases.67  In addition to an increase in susceptibility, 
combinations of individual variants may also be expected to determine the severity of chronic 
disease phenotype in patients with already existing disease. In childrens asthma, for example, a 
greater cumulative risk of severe asthma associated with the presence of multiple ‘risk’ variants, 
that are known to be individually associated with increased asthma severity, may determine why 
one child progresses towards regular multi-drug therapy and relatively frequent requirements of 
courses of oral steroids, while another remains well-controlled on occasional puffs of ‘reliever’ 
medicine or a modest, regular dose of inhaled steroids.  
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Some forms of genetic variation may influence the response to medication. This is particularly 
true of the β2 adrenoreceptor gene variation, as discussed above. The clinical importance of the 
variation could be tested by randomly allocating patients carrying the “at-risk” genotype to two 
different forms of medication, one of which is ‘standard’ and the other is the alternative 
medication, to which they are more likely to respond, if the hypothesis of reduced efficacy based 
on gene status is correct.  
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Chapter 5 
 
CLINICAL TRIALS IN ASTHMA FOCUSING ON THE RELATIONSHIP BETWEEN 
BETA2 AGONIST USE AND ARG/GLY VARIATION 
 
I have performed a literature review using a pre-defined search strategy in order to identify, and 
subsequently study, clinical trials in asthma that have used stratification by genotype.  
The search was performed using the Pubmed and Web of Knowledge databases.  The keywords 
‘asthma’, ‘genotype’ and ‘trial’ were used for the search.  I could not identify any randomised 
controlled trials with stratification by genotype in the field of children’s asthma.  I explored 
studies of participants with asthma carrying one or two copies of Arg16 genotype, where 
genotype was established retrospectively or prospectively.  I concentrated on current studies, 
restricting my searches to the period 2000 – 2014, in order to develop a fuller understanding of 
the current literature.  
 
Studies involving short-acting βeta2-agonists (SABAs) 
One of the first genotype-stratified, prospective placebo-controlled trials in adults in this area 
was the BARGE trial (Beta-Adrenergic Response by Genotype).68  This study was designed to 
compare the effects of regularly scheduled use of inhaled albuterol in patients with mild to 
moderate asthma with either Arg/Arg or Gly/Gly genotype variation at the β2 -adrenoreceptor.   
The hypothesis for this study was that regular administration of inhaled albuterol, compared to 
placebo, will have a detrimental effect on asthma control in subjects with the Arg/Arg 16 
genotype.  In contrast, regular albuterol will have no significant effect, compared to placebo, in 
patients with asthma of a similar baseline severity with the Gly/Gly genotype. 
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Seventy eight participants – adults - were randomised to either regular salbutamol or placebo for 
16 weeks, followed by a crossover in treatment for another 16 weeks. Arg/Arg subjects had lower 
peak expiratory flow rates during treatment with regular albuterol compared with placebo. 
 
Litonjua et al used a novel family screening algorithm based on the statistical power of each 
single polymorphism (SNP) to rank 844 SNPs in 11 bronchodilator response candidate genes in a 
cohort of 209 children and their parents participating in the Childhood Asthma Management 
Program (CAMP).69 
 
Martinez (1997) performed a birth cohort study to compare response to a single dose of 
salbutamol.70 The participants were of Hispanic or Caucasian descent.  Two hundred and sixty 
nine children were genotyped and asked to report episodes of wheezing during the previous year.  
Children who were homozygous for Arg16 were 5.3 times more likely to respond to a single dose 
of salbutamol than the children who were homozygous for Gly16.  
 
Ethnic-specific pharmacogenetic differences in the effect of Arg16Gly genotype on drug 
response were demonstrated in a study of Latino Americans with asthma.  Significant 
associations were found between the number of Arg16 alleles and responsiveness to a single 
dose of salbutamol among asthmatic Puerto Ricans with a baseline FEV1<80% predicted.  This 
relationship was not present in Mexican asthmatics.71 
 
The relationship between the long-term use of SABAs and the Arg16Gly genotype has also been 
studied.   Participants were stratified by genotype for Arg16Gly and Glu27Gln and then 
randomised to receive regular plus as-needed salbutamol or as-needed salbutamol.69 Regular 
SABA use was associated with a decline in morning and evening PEFRs in adult patients who 
were homozygous for Arg16, but not other genotypes. 
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Studies involving long-acting βeta2-agonists (LABAs) 
Bleecker et al performed a similar analysis but found contradictory results, with no evidence of 
association between the Arg16Gly genotype and response to salmeterol in combination with 
inhaled corticosteroid (ICS).73  This led to two larger, genotype-stratified, randomised controlled 
trials.  In the LARGE (Long-Acting Beta Agonist Response by Genotype) study73, a total of 87 
adult patients were randomised to 18 weeks of treatment with salmeterol or placebo with a 
subsequent crossover.  Open-label use of beclomethasone and ipratropium bromide was allowed 
throughout the trial. The LARGE study examined polymorphisms of ADRB2  in participants 
previously enrolled in clinical trials involving the LABA salmeterol. They found that Arg/Arg 
patients had a decrease in PEFR and diminished therapeutic response to the regular use of 
salmeterol, compared with those with Gly/Gly. Both Arg/Arg and Gly/Gly patients showed 
improved PEFRs after treatment with salmeterol. However, this study's impact was limited by its 
small sample size.   
Recently, Bleecker et al74 published the results of a large genotype-stratified clinical trial where 
544 adult asthmatic subjects with Arg/Arg, Gly/Gly or Arg/Gly at codon 16 were randomised to 
salmeterol alone or in combination with inhaled fluticasone propionate, for 16 weeks. Both 
Arg/Arg and Gly/Gly subjects showed improvement in morning PEFR with salmeterol alone and 
salmeterol in combination with fluticasone propionate, although the differences in PEFR were 
not statistically significant.  Furthermore, Arg16Gly genotypes did not modify other secondary 
treatment responses, including evening PEFR, FEV1, as-needed ipratropium bromide use and 
percentage of symptom-free days. The authors conclude that there was no evidence of a 
pharmacogenetic effect of ADRB2 gene polymorphisms on salmeterol response, in particular at 
the Arg16Gly position.  
The SMART trial (Salmeterol Multicenter Asthma Research Trial)75 is a randomised controlled 
trial comparing the safety of salmeterol or placebo added to usual asthma care.  Interim analysis 
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showed that significantly more African Americans prescribed salmeterol experienced 
respiratory-related death or life-threatening experiences compared with those prescribed placebo. 
Because of these preliminary findings in African Americans and difficulties in enrollment, the 
trial was stopped prematurely.  
Overall, although the combined findings from the LABA studies may be reassuring, the use of 
LABA monotherapy remains contraindicated in the treatment of asthma because of the increased 
risk of severe exacerbation of asthma symptoms in some patients. Various studies have identified 
a role for Arg/Gly variation on the β2 receptor gene that may influence the response to SABAs 
and LABAs.  This pharmacogenetic response also varies by ethnic group. Most of the literature 
has focused on the use of SABA and LABAs with regard to safety. This is important as these 
medicines represent a widely prescribed class of asthma medication.  
The retrospective observational study carried out in Tayside in 2006 found increased 
exacerbations in asthmatic children with the Arg /Arg 16 polymorphism, especially those using 
inhaled salmeterol.63   Data from 546 asthma sufferers between the ages of 4 and 21 years were 
examined.  The population carrying the Arg/Arg-16 genotype variant (13%) and prescribed 
inhaled long-acting β2 agonists, was found to be less well controlled, with 70% of this population 
having had significant asthma exacerbations within the six month trial observation period.  In 
comparison, exacerbations occurred in only 33 % individuals with the Gly/Gly polymorphism of 
the ADRB2.  Also of note, it was found that, in the children receiving salmeterol, the adjusted 
odds ratio showed a 9 fold (p=0.003) greater risk of school absences due to asthma in the 
Arg/Arg group in comparison to the Gly16 carriers, with an unadjusted odds ratio of 6 (p=0.009).  
In the cohort not receiving salmeterol, there was no evidence of any genotype-dependent 
increases in school absences due to asthma (odds ratio=1).  In addition, the Arg/Arg children on 
salmeterol had a significantly increased risk of extended school absence of over 1 week from 
asthma with an adjusted odds ratio of 6 (p= 0.019).  
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Conclusion 
Information about medication effects on asthma provides opportunities to design studies that will 
guide improvement in asthma care which could lead to further information in how best to target 
treatments to those patients who would benefit most  i.e. to stratify a population needing 
treatment into those likely or unlikely to respond to treatment. 
  
This forms the background to one of the first randomised controlled studies on a genotype 
stratified population of asthmatic children. This represents the main study within my thesis. 
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SECTION 2 - METHODS 
 
Chapter 6 
 
REGULATORY AND LEGAL PROCEDURES AND APPROVALS 
 
In this chapter I would like to describe the processes in which I was involved prior to beginning 
the clinical phase of the study.  The following are mandatory procedures to safeguard the rights 
and well being of potential participants and assist researchers produce credible results. 
 
Regulatory & Legal Procedures 
Regulatory and legal procedures were approved by University of Dundee, Tayside Research 
Ethics Committee and the Research and Development Department for NHS Tayside and because 
the study involved medicinal products, the Medicine Healthcare Regulatory Authority (MHRA) 
also provided an official review of study documents, facilities, and resources. 
 
Study Sponsor  
Clinical Academics and Senior Consultants from the University of Dundee reviewed the protocol 
and scientific quality of the study.   
 
Funding 
The proposal directly follows on from observational research that had been peer-reviewed and 
accepted for fast-track publication in Thorax.63  The observational work had identified the 
adverse effect with the gene configuration and indicated a need for randomised controlled trials 
to evaluate benefit with the two commonly available modes of treatment at this stage of asthma, 
specifically in the population with the gene variation. This led to this proposal for research. The 
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proposal was reviewed and subsequently supported by the review process of pharmaceutical 
company Merck, Sharpe and Dohme through an unrestricted educational grant.  The work was 
also supported by funding from the University of Dundee Medical School, Scottish Enterprises, 
The Gannochy Trust, The Perth & Kinross Council and the Brighton and Sussex Medical School.  
 
Tayside Research Ethics Committee 
Once the protocol had been peer reviewed and funding provisionally secured subject to 
mandatory regulatory approval, the proposal was submitted to Tayside Research Ethics 
Committee (REC).76  The REC viewed the study protocol and documentation to ensure the 
research complied with ethical standards in the interests of the potential research participants i.e. 
children aged 5-18 years and their families.  Information leaflets for parents, and versions 
adapted for teenage and younger participants were checked for clarity and appropriateness for 
target groups (appendix 1).   
 
Approval was withheld after the first submission, but granted after alterations to the information 
leaflets to include explanation about confidentiality of study information, explanation to 
participants that data was anonymous and stored in a password protected computer, and finally a 
paragraph so that participants could read clearly that they could withdraw from the study at any 
time.  The committee also requested separate information was prepared for participants about the 
study medicines, how they work and potential adverse effects of the medicines. 
 
NHS Research & Development  
An application was submitted to NHS Tayside Research and Development Department to request 
permission to undertake research on NHS Tayside premises with its patients and staff.  The 
Research and Development Department performed a site specific assessment i.e. the suitability 
of the site and facilities for the research. 
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Appendix 1 
   RESEARCH INFORMATION SHEET FOR CHILDREN (5-12 YEARS) 
 
Title: Add-on salmeterol versus montelukast in patients with asthma carrying the Arg/Arg-16 
polymorphism (Add-on asthma medicines for children with special genes) 
 
This is an invitation to take part in a research study. 
 
Why have I been asked?  
You gave us a mouthwash sample for our Genes in Asthma study. By testing your mouthwash, we 
have found that you have a type of gene that will not allow one of your asthma medicines to work 
very well. This type of gene is present in about 1 in 8 persons.  Therefore it is likely that several of 
your friends will have this gene also. 
 
You may already be on these medicines or you may be given these medicines to take in next few 
years. Many young people are now being prescribed these medicines at an early stage in their asthma.  
 
There is an alternative medicine (montelukast as tablet) that is not affected by the type of gene that 
you have, so it may be a better drug for your asthma.  
 
We will find out which the two medicines is the right one for children like you who carry this gene. 
We will follow you up carefully and let you and your GP have your results at the end of the study.  
  
So, joining in could help your asthma. It will also help us find out more about asthma in children in 
Scotland. 
  
What does the study involve?  THERE ARE NO BLOOD TESTS. We will ask you to take either an 
inhaler and a sugar tablet or an inhaler and a montelukast tablet for 1 year. You will be checked 
carefully over three months by a nurse and doctor who is an expert in asthma. We will also do simple 
and easy-to-do tests at each visit to measure how much allergy and asthma you have.  
At the end of the year, we will let you and your doctor know whether the medicine has made your 
lung function and chest inflammation and your asthma better or worse.  
 
Who is checking the study? Before any research is allowed to happen, it has to be checked by a 
group of people who make up the Ethics Committee. They make sure that the research is OK to do. 
This project has been checked and approved by the Tayside Ethics Committee. Taking part in the 
research is entirely up to you and your parents.   
 
Who will know about my role in the study? The doctors and nurses taking part in your care will 
know about your role in the study. The University and the company supplying some of the medicines 
(MSD) may also know under special conditions.   The information collected about you will be stored 
by using a special code instead of your name on a computer that can only be accessed by a password.  
Only members of the research team will know your name and all the information collected will be 
stored securely at Ninewells Hospital for 15 years. 
 
Maternal  and  Child  Heal th  Sciences  
 
              
   Head of Department & James Mackenzie Professor of Child Health                       
   Professor Richard E Olver BSc MB BS FRCPCH FRCPE  FMedSci 
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What happens if a better medicine comes along? If a better treatment comes along, taking part in 
this study will not stop you getting it. 
Appendix 1 
 
What if I don’t want to do the research anymore? If at any time you don’t want to do the research 
anymore, just tell your parents, doctor or nurse. They will not be cross with you. Your doctor will 
help you decide which medicine is best to use afterwards. 
 
What if something goes wrong? The study only uses normal asthma drugs which are known to be 
safe. The nurse will be in touch with you to check that your asthma is under control. The nurse and 
the doctor will carefully follow up your treatment over the year and check for any problems with 
asthma control.  
 
 
Flow chart for the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for reading this Information Sheet and considering taking part in this study 
 
 
What is your name? ……………………………………………………………………… 
 
Would you like to take part in this project?    Yes ……………             No……………... 
 
Somnath Mukhopadhyay                                             Colin Palmer 
Donald Macgregor                                                              scientist   
Brian Lipworth 
Asthma doctors in Tayside Women’s and Children’s / Medical Directorate 
 
Leaflet version  2 date 06/2007 
 
Visit 1  
Visit to clinic review, lung function test  
Questions from nurse  
Mouthwash  
Start of asthma progress diary 
Start medicine  
 
Visit 2, 3, 4 (month 3, 6, 9)  
visit to a specialist nurse or doctor clinic for 
lung function test, mouthwash for allergy 
test, asthma diary  
Visit 5. month 12.  
Final visit 
Clinic, lung function test,  
Mouthwash/saliva sample  
Asthma progress diary  
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Medicines and Healthcare products Regulatory Agency – MHRA 
Clinical trials involving medicinal products require authorisation from the Medicine and 
Healthcare products Regulatory Agency (MHRA).  An application to MHRA requires detailed 
information about all aspects of the trial medicines, dosing, storage and the supplier of the 
medicines.  The Clinical Trial Pharmacist prepared an example of the labels to be used on the 
study tablets supplied to participants at each visit.  
 
MHRA requested modification to the study protocol before giving approval to commence the 
study.  The protocol was updated to include details of safety reporting procedures in accordance 
with the Clinical Trials Directive 2001/20/EC.77 
 
Clinical Trials Registration 
The trial was registered with ClinicalTrials.gov number NCT00655616.78  This web-based 
resource provides participants, family members, health care professionals, researchers, and the 
public access to information about clinical studies both publicly and privately supported on a 
wide range of diseases and conditions.  
 
Statistical Rationale:   
I was not involved determining number of subjects but have some limited understanding of 
process involved.  Before a study is conducted, researchers must determine how many subjects 
should be included. If too few subjects are enrolled, a study may not have enough statistical 
power to detect a difference. Enrolling too many patients could be unnecessarily costly or time-
consuming. 
 
The statistical analysis for the trial was based on pilot data and calculated using the software 
Statmate 2 for Macintosh and Graph Pad Software Incorporated (San Diego, California, US).  
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This package was used to determine the minimum number of subjects needed for the study in 
order to have sufficient statistical power to detect a treatment effect between the two study 
groups. 
 
Pilot work 
Pilot work in Tayside (BREATHE study)63 showed that 85% of asthmatic children who were 
Arg16 homozygous and prescribed regular salmeterol had one or more school absences over 6 
months, compared to 25% in those on inhaled steroids alone (i.e. a 60% difference).   This is 
known as the effect size.  If the effect size is large between the study groups then the sample size 
required for the study is less and if the effect size between the study groups is small, the sample 
size required is large.79 
 
Sample size required 
A sample of 30 patients in each arm was required to show a minimal important difference of 
60% in school absences over 1 year as the primary outcome for comparison between the 2 
groups, to achieve at least 80% power, with error of 0.05. 
 
Margin of Error (Confidence Interval)  
The confidence interval determines how much higher or lower than the population mean you are 
willing to let your sample mean fall. This is usually +/- 5% 
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Chapter 7 
 
STUDY DESIGN 
 
Study Description 
The study is randomised controlled (parallel design) to compare oral montelukast and inhaled 
salmeterol as add on therapy to inhaled corticosteroid treatment over a period of 1 year, in 
children aged 5-18 years with asthma carrying Arg/Arg 16 homozygous genotype.  
 
Primary Hypothesis 
• Children with asthma carrying the Arg/Arg-16 genotype have fewer school absences over 
a period of 1 year on oral montelukast in comparison to inhaled salmeterol 
 
Secondary Hypotheses 
• Children with asthma carrying the Arg/Arg-16 genotype require less rescue oral steroids 
over a period of 1 year on oral montelukast in comparison to inhaled salmeterol 
 
• Children with asthma carrying the Arg/Arg-16 genotype have less hospital admissions 
over a period of 1 year on oral montelukast in comparison to inhaled salmeterol 
 
• Children with asthma carrying the Arg/Arg-16 genotype have less overall asthma 
exacerbations (total school absence, hospital admission and need for oral steroids) over a 
period of 1 year on oral montelukast in comparison to inhaled salmeterol 
 
• Children with asthma carrying the Arg/Arg-16 genotype require less reliever medication 
over a period of 1 year on oral montelukast in comparison to inhaled salmeterol  
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• Children with asthma carrying the Arg/Arg-16 genotype have higher peak expiratory flow 
rate and higher forced expiratory volume at 1 second over a period of 1 year on oral 
montelukast in comparison to inhaled salmeterol. 
 
• Children with asthma carrying the Arg/Arg-16 genotype report less symptoms of cough, 
wheeze and dyspnoea in the morning and overnight over a period of 1 year on oral 
montelukast in comparison to inhaled salmeterol.  
 
• Children with asthma carrying the Arg/Arg-16 genotype have improved asthma specific 
quality-of-life over a period of 1 year on oral montelukast in comparison to inhaled 
salmeterol. 
 
Study Setting  
The study took place at the Children’s Asthma and Allergy Research Unit, Tayside, between 
August 2007 and August 2009.  The pragmatic design of the study helped make taking part more 
appealing and convenient for families because they could be seen at their normal clinical area at 
Ninewells Hospital and Medical School or Perth Royal Infirmary.  
 
Recruitment 
Demographic, clinical and β2 receptor genotype information from 546 children with physician 
diagnosed asthma was obtained from a previous Tayside study database known as BREATHE.  
Gene analysis of DNA from BREATHE study mouthwash samples determined that 154 
participants were homozygous for the Arg/Arg 16 genotype.  The BREATHE study consent form 
included a section requesting permission to contact the families about future research.  Each of 
the 154 participants with the Arg/Arg 16 polymorphism were invited to discuss the outcome of 
BREATHE study analysis and consider taking part in the present study. 
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Inclusion criteria 
Sixty two children and young adults agreed to participate in the study and fulfilled all the 
following criteria to take part in the study: 
• physician-diagnosed asthma  
• prescribed daily inhaled corticosteroid therapy.   
• history of at least one of the following within the previous 12 months: school absences as a 
result of asthma, need for course of oral steroids, visits to General Practitioner, out-of-hours 
service or hospital admissions with asthma. 
 
Exclusion criteria 
Children with other significant lung disease or multi-system disease e.g. cystic fibrosis, cancer 
under current treatment, were excluded from the study. 
 
Enrollment & Participant Numbers 
Figure 1 describes enrollment and the number of study participants.  The children with 
Arg/Arg16 genotype (154) were screened for eligibility.  Fifty two were not eligible to 
participate mostly because they no longer used inhaled corticosteroids, or if they were still 
prescribed inhaled steroids did not meet other inclusion criteria.  Forty children/families declined 
to participate for unspecified personal reasons.   
 
Number of Participants to complete Study 
All patients for whom follow-up data was available were included in the analysis, even if they 
did not complete all 5 visits i.e. withdrew from the study.  Twenty eight participants were 
randomised into one treatment group (ML).  Of these 28 participants in ML group, 27 completed 
the study by attending five scheduled visits.  Only one girl discontinued in this group due to 
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maternal concerns about possibly developing adverse effects from the trial medication, however 
no such effects were experienced by this girl whilst she was in the study. 
 
Thirty three participants were randomised into the other group (SM).  Of these 33 participants, 
28 completed the study and 5 participants withdrew.  Two participants decided to withdraw from 
the study due to perceived poorer control on study intervention treatment.  One participant 
disliked the accuhaler dry powder inhaler device, another exercised his right to withdraw because 
he no longer wished to take part and the final participant withdrew from study due to perceived 
adverse effect to treatment – tachycardia. 
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Figure 1: Enrolment and Number of Participants  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 were included in the primary 
analysis 
28 were included in the primary 
analysis 
154 children with Arg/Arg β2 receptor 
genotype were assessed for eligibility 
 
 
    
1 stopped taking active 
montelukast due to 
maternal anxiety and 
concerns about possible 
adverse effect, however 
no such effects were 
experienced whilst in the 
study 
2 discontinued due to poorer 
control on study medication 
 
1 did not like the Accuhaler 
dry powder inhaler device 
 
1 stopped all asthma treatment 
due to absence of symptoms 
 
1 experienced tachycardia as 
adverse effect to treatment 
 
 
 
52 did not meet inclusion 
criteria 
 
40 declined to participate 
62 randomised 
 
28 were assigned to receive 
montelukast and inhaled fluticasone 
(ML) 
34 were assigned to receive placebo 
montelukast and inhaled fluticasone 
combined with salmeterol (SM) 
47 
 
 
Informed Consent 
After screening, written consent was obtained.  Information about the study was sent to the 
families prior to initial meeting as stipulated by the REC committee.  The study was explained to 
participants and they were given opportunity to ask questions and consider whether they would 
like to take part.  Legally valid consent was obtained from the parents/guardians and also the 
agreement of school age children so both parents and children signed the consent form.  
Participants aged 16 years or older provided consent independently.  A copy of the study consent 
form follows (appendix 2). 
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                                       Add-on salmeterol versus montelukast in patients with asthma carrying the Arg/Arg-16 
polymorphism 
 
CONSENT FORM 
 
NB. This form must be completed and signed by the research participant and/ or parent/ guardian where appropriate 
in the presence of someone with knowledge of the research designated by the Principal Investigator.  This may be a 
doctor, nurse, clinical research assistant or other member of the research team who must countersign the form as 
witness to the participant’s and/ or parent/ guardian’s  signature 
Please tick () appropriate box 
 
Have you read and understood the participant Information Sheet?   Yes  No  
 
Have you been given an opportunity to ask questions and further discuss this study? Yes  No  
 
Have you received satisfactory answers to all of your questions?   Yes  No  
 
Have you now received enough information about this study?    Yes  No  
 
Who have you spoken to? Dr/Mr/Mrs/Miss  ……………………………………………………… 
 
Do you understand that your participation is entirely voluntary?   Yes  No  
 
Do you understand that you are free to withdraw from this study: 
 
• At any time?        Yes  No  
 
• Without having to give a reason for withdrawing?   Yes No  
 
• Without this affecting your present or future medical care?  Yes  No  
 
I agree that the pharmaceutical company MSD can have access to my/my child’s research and related records. 
          Yes  No  
 
Note that it is a statutory requirement that if you agree to take part in the study, your research records and, if necessary, 
your medical records are available for scrutiny by monitors of the sponsor organisation (which may be the NHS, 
University or a commercial organisation funding the study) and, in the case of clinical trials of medicines, the UK 
Regulatory Authorities. 
 
Do you agree to take part in this study?      Yes  No  
 
Participant’s signature …………………………………………….Date ……………….………………….. 
Participant’s name in block capital letters ………………………………………………………………….. 
Parent/ Guardian’s signature……………………………………….Date……………………………………… 
Parent/ Guardian’s name in block capital letters……………………………………………………………… 
Telephone contact (Parent/ guardian) ………………………….(Home)….………………………….(Work) 
Signature witnessed by  ………………………………………  Date .……………………………. 
Witness name in block capital letters ……………………………………………………………………….. 
THANK YOU for agreeing to take part in this research 
Version 3; 02 July 2007 
 
Maternal  and  Child  Heal th  Sciences  
 
  
   Head of Department & James Mackenzie Professor of Child Health                                                                   Appendix 2                  
Professor Richard E Olver BSc MB BS FRCPCH FRCPE  FMedSci 
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Recruitment Period & Randomisation into Treatment Groups 
Participants were recruited between 1st August 2007 and 31st August 2008.  The concealed web-
based randomisation programme was designed by study statistician, Dr Simon Ogston.  The 
Clinical Research Pharmacist held a copy of this to allow her to prepare trial medicinal products.  
After consenting to take part in the study, participants were randomly allocated to one of two 
treatments at the screening visit:   
 
Treatment Groups 
Treatment arm 1 – ML - Flixotide® (fluticasone propionate) via accuhaler dry powder inhaler 
device as per current inhaled steroid dose plus oral montelukast;  
 
Treatment arm 2 – SM - Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler 
dry powder inhaler device as per current inhaled steroid dose plus placebo montelukast.   
 
Study medicines  
Inhaled Salmeterol 
Salmeterol is an inhaled long-acting beta-agonist medication recommended by British Thoracic 
Society/Scottish Intercollegiate Guidelines Network when symptoms are inadequately controlled 
on inhaled steroids.18  Its mechanism is to relax the muscles of the small airways in the lungs and 
taken regularly it lasts 12 hours to keep the airways open.  In combination with fluticasone 
propionate, the preparation is known as Seretide (GSK).  Fluticasone propionate is a 
corticosteroid with an anti-inflammatory action that reduces swelling and irritation in the small 
airways. 
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Delivery Device 
A request was made to the General Practitioner of each participant to prescribe the new inhaled 
medication for the treatment group i.e. Fluticasone via accuhaler device for ML group or 
Seretide combination treatment via accuhaler device for SM group.  No effort was made to blind 
the prescribed inhaled medication i.e. participants could determine which group they had been 
allocated on collection of the new inhaler prescription.  Each group of participants was exposed 
to only one of the study interventions i.e. parallel design (figure 3).   
 
Oral Montelukast 
Montelukast is a leukotriene receptor antagonist.  Leukotrienes cause narrowing of the airways 
and inflammation in the lungs which can lead to asthma symptoms.  Montelukast blocks the 
leukotriene pathways. 
 
Placebo Montelukast 
The purpose of using placebo for montelukast was to exclude excipient effects, and to correct for 
the effects of concurrent administration of tablet and inhaler on compliance of either medication 
in both treatment groups.  
 
Active and placebo montelukast was prepared by the Clinical Trial Pharmacist within the 
hospital and a 3 month supply was dispensed to participants at each visit by Research personnel.  
The placebo products for montelukast 4 mg, 5 mg and 10 mg tablets were prepared and 
dispensed in labeled bottles in compliance with the requirements of Current Good Manufacturing 
Practices as specified by the European Union.  Good Manufacturing Practice (GMP)80 is that part 
of quality assurance which ensures that medicinal products are consistently produced and 
controlled to the quality standards appropriate to their intended use and as required by the 
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marketing authorisation (MA) or product specification. GMP is concerned with both production 
and quality control. 
 
The following doses and dosage regimens were used for the study 
Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast   
Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast 
Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast  
Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of 
montelukast 
Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of 
montelukast 
Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of 
montelukast 
Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of 
montelukast 
Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 
years and above 10 mg once daily. 
 
Study Visits (figure 2) 
Participants were asked to remain in the study for a period of one year with five visits at three 
monthly intervals.  On entry to the study, participant details were documented and a clinical 
history and examination undertaken.  Each participant was designated a study identification 
number derived from name initials, MSD from Merck, Sharpe and Dohme who provided some of 
study funding and participant number randomisation e.g. AB  MSD/12.  A study case report form 
was completed at each visit. (Appendix 3) 
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Figure 2:  Schematic diagram of the trial protocol 
 
 
 
            
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
              
 
 
 
 
 
 
Randomised to receive one of two treatment 
groups for period of one year 
Assign study identification number 
 
Flixotide (Fluticasone) as per current 
inhaled steroid dose via accuhaler dry 
powder device plus oral montelukast (ML) 
Final visit (month 12)    
• Lung function test, exhaled nitric oxide, eosinophilic 
cationic protein saliva sample 
• View inhalers & check inhaler technique, 
• Document school absences for asthma, hospital 
admission 
• Arrange follow up - primary or secondary care clinic
        
 
Follow-up visits (months 3, 6, 9)  
• 3- monthly visits to for review
• Lung function test, exhaled nitric oxide 
• eosinophilic cationic protein saliva sample 
• Juniper PAQLQ 
• View inhalers & check inhaler technique 
• Document school absences for asthma, hospital 
admission, use of short courses of oral steroids  
 
 
 
Seretide (salmeterol plus equivalent dose of 
fluticasone) via accuhaler dry powder device 
plus placebo for montelukast (SM) 
Baseline visit 
• Clinical history & examination  
• Check inhaler technique with accuhaler device 
• Issue Asthma Home Plan & discuss emergency 
management symptoms 
• Lung function testing, exhaled nitric oxide monitoring 
• Paediatric quality-of-life questionnaire (Juniper) 
• Eosinophilic cationic protein saliva sample 
• Document history of school absence for asthma, use of 
short courses of oral steroids, hospital admission 
• Start of asthma progress diary 
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Inhaler technique 
Current asthma medication was discontinued for the period of the study.  The accuhaler device 
was chosen to deliver fluticasone and seretide because it has a dose counter which helped 
monitor compliance.  Careful assessment of inhaler technique was necessary so that any study 
effect was not due to poor uptake of medication.   
 
Patient education 
Inhaled salbutamol via metered dose inhaler and volumatic device was used as rescue 
medication. Participants were given an individualised management plan detailing how to use 
salbutamol in the event of increased symptoms.  
 
Concordance monitoring 
At each visit the participant was asked to return the bottle of montelukast/placebo tablets even if 
there were still some tablets unused.  The remaining number of tablets was documented and 
returned to pharmacy for disposal and a new 3 month supply of tablets was issued at each visit.  
The participant was asked to bring along their inhaler to allow the investigator to check total 
number of actuations dispsensed on the dose counter at each visit.  Participant inhaler technique 
was also checked at each visit.   
 
Asthma Symptom Diary 
Participants were provided with an asthma symptom diary to record controller and reliever 
medication use and exacerbation symptoms. This was also returned every 3 months. 
Medication compliance review, spirometry, exhaled nitric oxide testing and safety and efficacy 
assessments were recorded each visit. The incidence of adverse events was recorded and serious 
adverse events were dealt with according to protocol as described in chapter 8.  
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Asthma exacerbations 
Asthma-related school absences, intake of oral steroids and admission to the hospital between 
visits were grouped as present or absent.  The total asthma exacerbation response was defined as 
the presence of any of these measures during the same period of time. This was again grouped as 
present or absent to create an asthma exacerbation yes/no response that is a valid measure of 
asthma severity.  
 
Use of reliever medication 
To compare the use of inhaled bronchodilator as reliever, it was classified as  
0 = none used during 3 month period,  
1 = occasional (more than once a week and less than daily use),  
2 = daily (200micrograms/day required for symptom control),  
3 = excessive use (use of more than one dose of 200 micrograms/day for symptom control).  
This was then grouped as less than daily use and daily or excessive use of reliever for symptom 
control.  
 
Exhaled Nitric Oxide & Pulmonary Function 
Exhaled nitric oxide (Aerocrine, Solna, Sweden) and pulmonary function (forced expiratory 
volume at 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), 
forced expiratory flow between 25% and 75% of vital capacity (FEF25%-75%)) (Micromed, 
Rochester, United Kingdom) were measured. A standard protocol was followed for spirometry.81 
 
Self reported asthma symptoms 
The self-reported asthma symptoms (cough, wheeze and dyspnoea at morning and over night) 
were classified as 0 = no symptoms, 1 = once or twice per month, 2 = once or twice weekly, 3 = 
daily symptoms.  
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RESEARCH STUDY CASE REPORT FORM - VISIT NO.  _____               Appendix 3 
PARTICIPANT STUDY NUMBER ____________________ 
 
                    Visit Date      /      /                /      /          
                           /      /                /      /          
                   • Study No   Last Visit      /      /                     
                                 
• Accompanied by Mother Father Other Relative           
                  Foster Carer Social Worker Other Unaccompanied          
                                   Height and Weight                 
                  Height (cm) Centile Weight (kg) Centile          
                Medication on arrival at clinic N.B. For bronchodilator, indicate whether normal use is prn or regular.          
                Drug Device Dose per puff Unit Dose 
Prescribed 
Frequency          
               
               
               
               
               
               
                  Assessment              
              • Is inhaler technique satisfactory? Yes No Not on inhaler  Unable to check          
                 Inhaler device viewed :   Number on dose counter:            
               • Self-Management Plan 
discussed? 
Yes No Does not have Not applicable          
                   If the patient has a Self-Management Plan, when was it last updated?       /      /           
                 • Diary/PEFR Chart seen? Yes No Does not keep Diary/PEFR chart             
                  Readings from PEFR Chart: Highest Lowest             
                  Since last visit                
                  • Bronchodilator use None Occasional Daily Excessive Unable to answer          
                 • How many courses of oral steroids?  Unable to answer             
                • How many hospital admissions?  Unable to answer             
                • Absence from school/nursery due to asthma None 1-2 days Up to 1 week          
                More than 1 week Unable to answer Not applicable          
                  Symptoms since last visit None  1-2 monthly  1-2 weekly  Daily  Unable to answer         
                  • At Night Cough               
                 Wheeze               
                 Dyspnoea               
                • Morning Cough               
                 Wheeze               
                 Dyspnoea               
                  • Exercise Rarely Running Hills/Stairs Walking Unable to answer          
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• Persistent Nasal Symptoms None  Runny  Sneezy  Blocked  Unable to answer  
Lung Function           
 PEFR FEV1 FVC FEV1/FVC F50 F25          
Predicted            l/min                  1                 l                 %            l/sec            l/sec          
Actual              l/min                  1                 l                 %              l/sec              l/sec          
% Predicted            %                %                 %              %            %          
 
 Was lung function technique satisfactory?  Yes   No  
 
Exhaled Nitric Oxide Reading 
 
 Was eNO technique satisfactory?  Yes   No  
 
 eNO reading   (ppb)                                             
 
 
 
Pharmacovigilance 
 Any adverse events where association with trial medication suspected?  Yes   No 
 
 
 If yes details of adverse event 
 
 
 
 Action taken   
Record in Case Report Form (CRF)  Yes     
 Not required     
Notify Sponsor   Yes     
 Not required   
Report to MHRA & Ethics   Yes    Not 
required  
Adverse Event Report form completed  Yes    
 Not required  
 
Quality of Life Questionnaire  
• Completed beginning consultation Yes  No   
 
    
       
       
       
       
 Next visit   Signature  
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       Asthma Specific Quality of Life  
To measure quality of life, the Juniper Paediatric Asthma Quality of Life questionnaire was used 
(appendix 4).  Validated for children aged 7-17years, it is designed to reflect both physical and 
emotional areas of daily life that children with asthma identified as being important and 
bothersome to them.  It can show small changes even when the clinical state is stable.  
 
Domains 
The items are in three domains:  
• Symptoms (n = 10)  
e.g. How much did COUGHING bother you in the past week? 
• Emotional function (n = 8)  
e.g. How often did you feel DIFFERENT OR LEFT OUT because of your asthma during the past 
week? 
• Activity Limitation (n = 5)  
e.g. How much have you been bothered by your asthma in PHYSICAL ACTIVITIES(such as 
running, swimming, sports, walking uphill/upstairs and bicycling) during the past week?  
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Appendix 4 
PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE 
 
I want you to tell me how much you have been bothered by your asthma during the past week. I will tell 
you which card to use. Pick the number that best describes how much you were bothered by your asthma 
during the past week. 
 
1.  (A) How much have you been bothered by your asthma in PHYSICAL ACTIVITIES (such 
as running, swimming, sports, walking uphill/upstairs and bicycling) during the past 
week? [BLUE CARD] 
2.    (A) How much have you been bothered by your asthma in BEING WITH ANIMALS     
 (such as playing with pets and looking after animals) during the past week?             
 [BLUE CARD] 
3.   (A) How much have you been bothered by your asthma in ACTIVITIES WITH 
 FRIENDS AND FAMILY (such as playing during school break and doing things with 
 your friends and family) during the past week? [BLUE CARD] 
4.   (S) How much did COUGHING bother you in the past week? [BLUE CARD] 
5.   (E) How often did your asthma make you feel FRUSTRATED during the past week? 
 [GREEN CARD] 
6. (S) How often did your asthma make you feel TIRED during the past week?               
 [GREEN CARD] 
7.      (E) How often did you feel WORRIED, CONCERNED, OR TROUBLED because of 
 your asthma during the past week? [GREEN CARD] 
8.     (S) How much did ASTHMA ATTACKS bother you during the past week?                
 [BLUE CARD] 
9.    (E) How often did your asthma make you feel ANGRY during the past week? 
 [GREEN CARD] 
10.    (S)   How much did WHEEZING bother you during the past week? [BLUE CARD] 
11.   (E) How often did your asthma make you feel IRRITABLE (grumpy*) during the past 
 week? [GREEN CARD] (*use only if patient does not understand the word "irritable") 
12.     (S) How much did TIGHTNESS IN YOUR CHEST bother you during the past week? 
 [BLUE CARD] 
13.  (E) How often did you feel DIFFERENT OR LEFT OUT because of your asthma 
 during the past week? [GREEN CARD] 
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Appendix 4 
14. (S) How much did SHORTNESS OF BREATH bother you during the past week?  
  [BLUE CARD] 
15.  (E) How often did you feel FRUSTRATED BECAUSE YOU COULDN'T KEEP UP  
 WITH OTHERS during the past week? [GREEN CARD] 
16.  (S) How often did your asthma WAKE YOU UP DURING THE NIGHT during the past 
 week? [GREEN CARD] 
17. (E) How often did you feel UNCOMFORTABLE because of your asthma during the past 
 week? [GREEN CARD] 
18.  (S) How often did you feel OUT OF BREATH during the past week? [GREEN  CARD] 
19.    (A) How often did you feel YOU COULDN'T KEEP UP WITH OTHERS because of 
 your asthma during the past week? [GREEN CARD] 
20. (S) How often did you have trouble SLEEPING AT NIGHT, because of your asthma, 
 during the past week? [GREEN CARD] 
21 (E) How often did you feel FRIGHTENED BY AN ASTHMA ATTACK during the past 
week? [GREEN CARD] 
22. (A) Think about all the activities that you did in the past week. How much were you bothered 
 by your asthma doing these activities? [BLUE CARD] 
23.     (S) How often did you have difficulty taking a DEEP BREATH in the past week?       
 [GREEN CARD] 
DOMAIN CODE: 
(S)    =    Symptoms  
(A)    =    Activity Limitation  
(E)     =    Emotional Function
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Format 
There are 23 questions using words that children themselves may use to describe their 
problems.  The response options are on a seven point scale where 1 indicates maximum 
bother and 7 no bother.  The participants were given a card on which the responses were 
listed with a number and a description (appendix 5) 
 
Individual items within the PAQLQ were equally weighted and results were expressed as 
the mean score per item for each of the domains as well as for overall quality of life. The 
scores were distributed as follows: symptom scores: range 10-70, activity limitation 
scores: range- 5- 35, emotional function scores: range- 8- 56.  Higher scores indicate 
better quality of life and 0.5 is the minimal clinically important difference.40 
 
The interviewer-administered version was used where Research Fellow or Nurse asked 
each question using the exact wording of the Juniper questionnaire, and the child 
answered with a number or phrase response from the answer card that best described his 
or her experiences during the previous week.  Participants were asked to answer without 
any help or direction from their parents or the researcher.   
Appendix 5 
 
 
 
 
 
 
 
 
 
1. ALL OF THE TIME 
2. MOST OF THE TIME 
3. QUITE OFTEN 
4. SOME OF THE TIME 
5. ONCE IN A WHILE  
6. HARDLY ANY OF THE TIME 
7. NONE OF THE TIME 
1. EXTREMELY BOTHERED 
2. VERY BOTHERED 
3. QUITE BOTHERED 
4. SOMEWHAT BOTHERED 
5. BOTHERED A BIT 
6. HARDLY BOTHERED AT 
ALL 
7. NOT BOTHERED 
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Chapter 8 
 
PHARMACOVIGILANCE & MONITORING OF ADVERSE EVENTS 
 
An important aspect of clinical trial work is understanding pharmacovigilance and 
procedures to monitor adverse events that occur especially when the trial involves 
medicines.  In this chapter I discuss pharmacovigilance in the trial and the safety 
reporting during the trial. 
 
Pharmacovigilance and safety reporting: 
Any untoward medical occurrence affecting the participants during the course of the trial, 
referred to an adverse event, must be reported in accordance with the Medicines for 
Human Use (Clinical Trials) Regulation 200482 e.g. one participant was admitted to 
hospital for an unrelated incident during the trial and in accordance with local guidelines 
a form was completed to inform Research Ethics department.  No further action was 
required in this event because no serious event happened to participant and the reason for 
hospital admission was unrelated to the trial medicines. 
 
Definitions of Other Possible Events: 
Serious Adverse Event (SAE) 
A SAE is an adverse event where the participant has died or where a participant was 
admitted to hospital over a prolonged period, or if a participant had sustained persistent 
or significant disability or incapacity.   
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There were no SAE’s in the trial.  The definition of an SAE required us to consider that 
other adverse events may fall into the ‘serious’ category if they were important medical 
events (other than those listed in definition above) e.g. requiring medical investigation or 
intervention. 
 
Adverse Reaction (AR) 
An adverse reaction is when there is at least a possibility that the cause of an event is 
linked to the trial medicine. 
 
Serious Adverse Reaction (SAR) 
A serious adverse reaction (SAR) is a serious adverse event (SAE) that is thought to be 
linked to the trial medicine or intervention. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR) 
A serious unexpected serious adverse reaction (SUSAR) is defined as an unexpected 
occurrence of a SAR. This could be a previously unreported reaction to a trial medicine, 
or a previously reported but worsening or unexpectedly frequent adverse medicine 
reaction. 
 
Procedure for Recording and Notification: 
Participants and their family were asked if they had experienced any symptoms or events 
that may have occurred since their previous visit.  An assessment was made of causality 
and recorded this in the case report form (CRF).   There were 7 adverse events during the 
trial period.  Fortunately none of these were considered to be in the serious category. 
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If the events had fallen into the serious category where the event may have or had the 
potential to affect their continued participation in the trial, the study sponsor, University 
of Dundee, would have been notified.  It was not felt necessary to notify the study 
sponsor of admissions to hospital with acute asthma that can be anticipated with the 
natural course of the disease.  The investigator did not notify the sponsor of any serious 
adverse reaction which was already described in the summary of product characteristics 
for the study drugs, montelukast and seretide, unless it affected or had the potential to 
affect the continued participation of the subject in the study. 
 
The procedure for notification was laid down as follows.  The investigators notified SAEs 
or SAEs at the earliest convenient time after the investigator became aware of the event. 
The immediate report provided a limited amount of detail, including the subject’s unique 
identifier, gender and age plus a brief statement of the event.  For this purpose, there is a 
dedicated email address is provided by NHS Tayside, 
pharmacovigilance.tayside@nhs.net .  A detailed written report followed, containing all 
the information required by the sponsor for onward reporting to the Regional Ethics 
Committee.  This would have also included MHRA if there had been an adverse reaction 
during the trial.  
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Study Adverse Events  
 
• Participant no. 2 admitted to short stay ward Ninewells due to intoxication from 
alcohol and possible drug ingestion 
 
• Participant no. 48 randomised into placebo group (seretide 125mcgs b.d.).  
Mother felt him to be hyperactive and he reported palpitations.  Parent made 
decision to stop treatment (withdraw from study) & not to see G.P. or Research 
staff to discuss 
 
• Participant no. 58 developed coryzal symptoms.  Saw G.P. no change to 
treatment.  Cough began again.  Saw G.P. 9/04/08 questioned whether related to 
new accuhaler.  Participant decided to withdraw from study 
 
• Participant no. 38 admitted to ward 29 Ninewells Hospital due to acute asthma.  
Treated with oral steroids  
 
• Participant no. 38 readmitted to ward 29 Ninewells Hospital due to ongoing 
asthma symptoms  
 
• Participant no. 6 required oral steroids and antibiotics due to worsening asthma. 
Feels quality of life worsened since stopping pre-trial medicines 
 
• Participant no. 31 admitted to ward 29 Ninewells due to acute asthma.  Treated 
with oral steroids & nebulised bronchodilators  
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Risk Assessment of medicinal products: 
The investigation of medicinal products used in the study, montelukast and seretide, were 
used in their licensed dosage forms. Both drugs have been widely used in the treatment of 
childhood asthma for over 10 years. Their side effect and toxicity profiles are therefore 
already well-established in the study population.   
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     Chapter 9 
 
STATISTICAL METHODS 
 
Statistical analysis   
I was involved in collection of the data and entered data onto the results database in  
preparation for analysis.  I did not directly carry out the analysis but have tried to gain an 
understanding of the process of analysis of data in a clinical trial.  All participants from 
both groups were included in the intention-to-treat analysis.  No interim analysis was 
performed before completion of the trial. 
 
Software Packages 
The analysis was performed using the Statistical software Package for the Social Sciences  
referred to as SPSS.  This is compatible with Windows version 16 (SPSS Inc, Chicago, Ill).   
Prism (GraphPad Software Inc) software package was used to analyse and present the data 
in graphs.   
 
Baseline calculations 
Means (Standard Deviations) were calculated for baseline variables.  Comparisons were 
made by an overall analysis of variance, and Bonferroni-corrected, multiple-range 
testing.79 
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Means (Standard Deviations) 
Bonferroni-corrected, multiple-range testing 
Bonferroni correction, named after Italian mathematician Carlo Emilio Bonferroni, is a 
statistical method used to counteract the problem of multiple comparisons. 83  
 
Comparisons 
Comparisons refer to the 2 treatment groups.  Efficacy was compared between the two 
treatment groups, montelukast and salmeterol, in terms of the reduction of any one of a 
number of disease symptoms.  Where more symptoms are considered, it becomes more 
likely that there will appear to be an improvement in one medicine or the other in at least 
one of the symptoms.  Multiple comparisons arise when a statistical analysis 
encompasses a number of comparisons.  
 
For the study means (SDs) were calculated as descriptive statistics for baseline variables.  
Comparisons were made by an overall analysis of variance, followed by Bonferroni-
corrected, multiple-range testing, to obviate multiple pair wise comparisons between 
baseline and the two treatment groups, with the overall error set at P<.05.  A mixed-
effects linear model for longitudinal data analysis was used as we had obtained repeated 
measurements of the primary and secondary outcome variables over time. Outcome 
variables based on daily symptoms and diary records were averaged over all the days 
between clinic visits.  
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Mixed-effects linear model for longitudinal data analysis 
Data generated by observing a number of individuals repeatedly under differing 
experimental conditions where the individuals are assumed to constitute a random sample 
from a population of interest.83  Our study was designed to compare mean responses over 
time among 2 groups of individuals.  For balanced and complete data, a generalized 
multivariate analysis of variance is used (ANCOVA).   
Assessing normality of data using parametric testing 
When choosing analysis or which statistical test to perform it is important to determine  
whether you have data that allows for parametric or non-parametric testing.  The SPSS  
package allows the user to assess whether their data is normal.  Parametric testing  
assumes that the data is normal.  Parametric testing uses more information than non- 
parametric tests and are therefore usually more powerful.83  
 
Probability (P)  
The probability (p) value indicates how likely it is that the result of the study could have 
arisen by chance alone.  Results were considered significant if the probability was 0.05 or 
less.79 
 
Confidence intervals 
Confidence intervals were used because the P value does not tell us about the size of the 
effect.  Confidence intervals tell us how much the play of chance might have altered the 
result.  Chance variation becomes smaller and the confidence interval narrower where 
more participants are studied.79,83 
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Error bars 
Error bars represent 95% confidence intervals.83  P values are shown for the comparison 
between the two treatment groups through the treatment period.  
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SECTION 3 - RESULTS 
 
Chapter 10 
 
In this chapter I will to display study results.  The first chapter provides a summary of 
baseline characteristics of participants obtained at entry to the study.  Following this there 
is a short description of the results obtained for each outcome in the study and a graph to 
illustrate the result.  
 
BASELINE CHARACTERISTICS  
 
It is important to show that any differences between the study groups at start of the trial 
was not a factor in the overall analysis.  A comparison of the baseline characteristics of 
study participants in each group was made.  The results are divided into two treatment 
groups – inhaled Fluticasone and montelukast (ML) and inhaled Fluticasone with 
salmeterol and placebo montelukast (SM) to show asthma control in each group over the 
previous year prior to entry into the study.  Overall participants in both groups had well 
controlled asthma.   
 
Age in years; study population; body mass index at baseline 
Mean age in years of participants at randomisation was calculated by dividing the sum 
total of ages in each group with the number of participants in each group.  Participants in 
the SM group were slightly older (11.79 years) compared to 10.50 years for the ML 
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group.  The study population is similar to the general population of children with asthma 
where the prevalence of asthma in boys known to be greater than in girls.85 In each 
treatment group the percentage of boys is 56% and 71%.  Both groups were within 
normal range for body-mass index (weight in kilograms divided by the square of the 
height in meters).  None of these differences were significant at baseline. 
 
Asthma control prior to entering study  
The degree of asthma control at baseline was assessed by recording how frequently 
participants required short acting beta agonists over the three month period prior to 
entering the study.  A high percentage, 96 % in ML and 91% in SM of participants 
reported using salbutamol at least twice weekly at baseline.   
 
Participants were asked if they had required any short courses of oral steroids, had 
asthma-related school absences, or had any exacerbations resulting in hospital admission 
within the year prior to entering the study.  A high number of participants in each group 
reported school absences due to asthma – 96% in ML group and 92% in SM group.  
School absence  was one of the inclusion criteria for the study.  22% of ML and 15% of 
SM group reported an asthma exacerbation requiring admission to hospital within the 
previous year.  None of these differences were significant at baseline.   
 
There was a significant difference in pre-treatment requirement of oral steroids due to 
asthma exacerbations in the previous year (p = 0.011) between the two treatment groups.  
This could have suggested this group had more severe asthma at baseline and more 
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potential room for improvement, compared to the salmeterol group.  To demonstrate that 
this difference was not a factor in the overall analysis the ANCOVA model was used.   
 
ANCOVA analysis  
ANCOVA (analysis of co-variance) analysis allows researchers to demonstrate they have 
considered the statistical effect initial differences (in this study oral prednisolone use) and 
provide as accurate picture as possible that this did not affect overall effect of the two 
treatments.83 
 
Baseline Pulmonary function: Peak expiratory flow rate (PEFR); Forced expiratory 
volume in one second (FEV1 ); Forced vital capacity (FVC) at baseline 
All participants in both groups were able to perform baseline pulmonary function 
measurements.   
 
Asthma scores from Paediatric Asthma Quality of Life Questionnaire (PAQLQ) at 
baseline 
The Juniper Paediatric Asthma Quality of Life questionnaire was used to show how 
participants perceived their asthma symptoms and the effect of asthma on their every day 
life.  Higher scores indicate better quality of life and 0.5 is the minimal clinically 
important difference.  Pre-treatment mean PAQLQ symptom scores of 5.67 (ML) and 
5.52 (SM), activity limitation scores of 5.71 (ML) and 5.71 (SM), and emotional function 
scores of 6.09 (ML) and 5.91 (SM) were observed.  None of these differences were 
significant at baseline. 
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Self reported asthma symptoms at baseline 
Participants and/or their parents were asked to summarise the frequency with which they 
were troubled by cough, wheeze and dyspnoea both overnight and in the morning, over 
the 3 months before entering the study.  Overall a larger percent of participants about to 
enter the ML treatment group reported most asthma symptoms of cough, wheeze and 
dyspnoea. However, these differences did not reach significance at baseline. 
 
Daily inhaled corticosteroids & modified British Thoracic Society (BTS) step of asthma 
treatment at baseline 
All participants had been prescribed inhaled corticosteroids at the point of entry to the 
study.  This was also criteria for entry in the study.  The level of asthma severity 
according to the British Thoracic Society stepwise guidelines was recorded.  The number 
of participants at step 2 treatment i.e.on regular inhaled steroids and inhaled β2 agonists 
as and when required was very similar (39% in ML and 41% in SM). There were fewer 
participants at step 3 in the ML group (11%) compared to 35% in SM, (i.e.prescribed step 
2 treatment with addition of inhaled long acting β2 agonists). 50% in ML group and 24% 
in SM were at step 4 (Step 3 treatment and montelukast). None of these differences were 
significant at baseline. 
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Chapter 11 
 
COMPARISON OF END OF STUDY OUTCOMES 
 
In this chapter I have prepared a graph for each outcome of the study.  Results are divided 
into two treatment groups – inhaled Fluticasone and montelukast (ML) and inhaled 
Fluticasone with salmeterol and placebo montelukast (SM).  Each figure describes the 
comparison made at each visit over the one year period of study.  Error bars represent 
95% confidence intervals and the p value is shown. 
 
Exacerbations 
The number of episodes of asthma-related school absences, requirement of short courses 
of oral steroids and the occurrence of exacerbations over the study period between the 
two treatment groups were compared. A significant difference was observed between the 
treatment groups for the primary outcome of the study, asthma-related school absences 
(0.40 (95% CI, -0.07-0.87; p=0.005)) (figure 3). No significant difference was observed 
for requirement of one or more courses of oral steroids (0.13 (95% CI, -0.07-0.34; 
p=0.202) (figure 4) and hospital admissions (0.03 (95% CI, -0.09-0.02; p=0.241) (figure 
5) during the study period. However, when considering total exacerbations (including all 
3 of the above individual measures), there was a significant difference over the study 
period in the ML compared to SM (0.39; 95% CI, -0.20-0.99; p=0.049) (figure 6). 
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Comparison of mean asthma related school absences while assigned to receive treatment 
with fluticasone plus montelukast (ML) or fluticasone plus salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported the number of school 
absences at 3 monthly follow-up visits (1 – 4).   
0 = no school absence;  
1 = 1-2 days school absence;  
2 = up to one week school absence. 
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups.   
 
*  Significant differences were observed (p = 0.005).  Participants in the ML group had 
fewer school absences in comparison to the SM group.   
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Comparison of the mean number of courses of oral steroids required to control 
exacerbations while assigned to receive treatment with fluticasone plus montelukast (ML) 
or fluticasone with salmeterol and placebo montelukast (SM).  Participants and/or their 
parents reported at 3 monthly follow-up visits (0 – 4) during study period of 12 months.   
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups.   
 
No significant difference was observed between the treatment groups in the individual 
measures for requirement of one or more courses of oral steroids (p = 0.0525).   
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Comparison of mean asthma related hospital admissions while assigned to receive 
treatment with  
fluticasone plus montelukast (ML), or fluticasone with salmeterol and placebo 
montelukast (SM), reported at 3 monthly follow-up visits (0 – 4) during the study period 
of 12 months.   
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups.   
 
No significant difference was observed between the treatment groups in the individual 
measures for hospital admissions (p = 0.1415).   
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Comparison of mean total exacerbations defined as either school absences, courses of 
oral steroids, or hospital admissions while assigned to receive treatment with fluticasone 
plus montelukast (ML), or fluticasone with salmeterol and placebo montelukast (SM).  
Participants and/or their parents reported if child had experienced any exacerbations at 
3 monthly follow-up visits (0 – 4) during the study period of 12 months.   
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups. 
 
* Significant differences were observed (p = 0.0280).  Participants in the ML group had 
fewer exacerbations in comparison to the SM group.   
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Chapter 12 
 
 
COMPARISON OF END OF STUDY OUTCOMES 
 
 
Bronchodilator use and Pulmonary function  
 
The use of reliever medication was significantly decreased in ML compared to SM  
(figure 7). During the study period, daily or more frequent use of short acting β2-agonist 
as reliever in the participants in the SM group did not alter over time (baseline 32%, 
3months 38%, 6months 32%, 9months 38%, 12months 35%). However, in ML, the 
requirement for daily or more frequent inhaled short acting β2-agonists was reduced over 
the study period (baseline 36%, 3months 18%, 6months 14%, 9months 11%, 12months 
18%). 
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Comparison of use of inhaled bronchodilator medication for control of asthma symptoms 
between treatment groups - fluticasone plus montelukast (ML) and fluticasone and 
salmeterol with placebo montelukast (SM).  Participants and/or their parents reported 
how much bronchodilator inhaler they had required at baseline and 3 monthly follow-up 
visits (0 – 4) during the study period of 12 months.   
 
0 = no reliever medication used,  
1 = occasional reliever medication used (more than once a week and less than daily use)  
2 = daily (200micrograms/ day required for symptom control).   
 
Error bars represent 95% confidence intervals and the plots represent the mean score for 
each group.   
 
* Significant differences were observed (p< 0.0001).  Participants in ML group used less 
bronchodilator than in SM group.   
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Comparison of mean values of peak expiratory flow rate (PEFR) readings shown as 
percent predicted (Zapletel) between two treatment groups - fluticasone plus montelukast 
(ML) and fluticasone with salmeterol and placebo montelukast (SM).  This was recorded 
at baseline and 3 monthly follow-up visits (0 – 4) during study period of 12 months. 
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups through the 12 month treatment period.   
 
No significant differences were found between the groups (p=0.164).  
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Comparison of mean values of forced expiratory volume in one second (FEV1) readings 
shown as percent predicted (Zapletel) between two treatment groups - fluticasone plus 
montelukast (ML) and fluticasone with salmeterol and placebo montelukast (SM).  This 
was recorded at baseline and 3 monthly follow-up visits (0 – 4) during study period of 12 
months. 
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups.   
 
No significant differences were found between the groups (p=0.152).  
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Chapter 13 
 
COMPARISON OF END OF STUDY OUTCOMES 
 
Parent or Self reported symptoms of Cough, Wheeze or Dyspnoea 
Through the study period, the self reported symptoms of cough, wheeze and dyspnoea 
improved significantly in ML group compared to SM. In particular, early morning 
symptoms were significantly improved in ML (morning cough 0.51 (95%CI, 0.09-0.92; 
p=0.018) (figure 10); morning wheeze 0.55 (95% CI, 0.25-0.86; p=0.001) (figure 11); 
morning dyspnoea 0.29 (95% CI, 0.06-0.53; p=0.008) (figure 12)). There was no 
significant difference in night cough between the treatment groups (0.29, (95% CI, -0.06-
0.63; p=0.238)) (figure 13). However, wheeze and dyspnoea at bedtime were improved in 
ML compared to SM (night wheeze 0.46 (95% CI, 0.15-0.77; p=0.004) (figure 14), night 
time dyspnoea 0.44 (95% CI, 0.16-0.73; p=0.001) (figure 15)).  
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Comparison of mean reported morning cough symptoms between two treatment groups - 
fluticasone plus montelukast (ML) and and fluticasone with salmeterol and placebo 
montelukast (SM).  Participants and/or their parents reported how much cough in the 
morning the child experienced at baseline and 3 monthly follow-up visits (0 – 4) during 
the treatment period of 12 months.   
 
0 = no reported cough,  
1 = occasional cough (more than once a week and less than daily use)  
2 = daily reported cough in the morning.   
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups. 
 
* Significant differences were observed (p = 0.018).  Less morning cough was reported 
in ML group compared to the SM group.   
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Comparison of mean reported morning wheeze symptoms between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported how much wheeze in the 
morning the child experienced at baseline and 3 monthly follow-up visits (0 – 4) during 
the treatment period of 12 months.   
 
0 = no reported wheeze,  
1 = occasional wheeze (more than once a week and less than daily use)  
2 = daily reported wheeze in the morning.   
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups. 
 
* Significant differences were observed (p = 0.001) i.e. less morning wheeze was 
reported in ML group compared to the SM group.  
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Comparison of mean morning dyspnoea symptoms between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported how much dyspnoea in the 
morning the child experienced at baseline and 3 monthly follow-up visits (0 – 4) during 
the treatment period of 12 months.   
 
0 = no reported dyspnoea,  
1 = occasional dyspnoea (more than once a week and less than daily use)  
2 = daily reported dyspnoea in the morning  
 
Error bars represent 95% confidence intervals and p value is shown for comparison 
between the two treatment groups. 
 
* Significant differences were observed (p = 0.008) i.e. participants in ML group 
reported less morning dyspnoea compared to SM group.  
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Comparison of mean cough symptoms overnight between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported how much cough through 
the night the child experienced at baseline and 3 monthly follow-up visits (0 – 4) during 
the treatment period of 12 months.   
 
0 = no reported cough  
1 = occasional cough (more than once a week and less than daily use)  
2 = daily reported cough in the morning   
 
Error bars represent 95% confidence intervals and p values are shown for the 
comparison between the two treatment groups.  
 
There were no significant differences (p = 0.238) between the two groups.  
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Comparison of mean wheeze symptoms overnight between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported how much wheeze through 
the night the child experienced at baseline and 3 monthly follow-up visits (0 – 4) during 
the treatment period of 12 months.   
 
0 = no reported wheeze  
1 = occasional wheeze (more than once a week and less than nightly)  
2 = daily reported wheeze overnight.   
 
Error bars represent 95% confidence intervals and p values are shown for the 
comparison between the two treatment groups.  
 
* Significant differences were observed (p = 0.001) i.e. participants in ML group 
reported less night wheeze compared to the SM group. 
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Comparison of mean dyspnoea symptoms overnight between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Participants and/or their parents reported how much dyspnoea 
through the night the child experienced at baseline and 3 monthly follow-up visits (0 – 4) 
during the treatment period of 12 months.   
 
0 = no reported dyspnoea 
1 = occasional dyspnoea (more than once a week and less than daily use)  
2 = daily reported dyspnoea at night.   
 
Error bars represent 95% confidence intervals and p values are shown for the 
comparison between the two treatment groups. 
 
* Significant differences were observed (p = 0.001) i.e. participants in ML group 
reported less night dyspnoea compared to the SM group.  
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Chapter 14 
 
COMPARISON OF END OF STUDY OUTCOMES 
 
Asthma related quality of life 
Over the year, significant differences were observed between the asthma quality of life 
scores in the 2 groups (figure 16) with greater improvement in all the scores in the ML 
group compared to the SM group. The difference for the overall mean score was 0.53 
(95%CI, -0.864- -0.189; p = 0.003) in ML compared to SM. While comparing the mean 
scores for individual domains between the two treatment groups over the study period, 
significant differences in improvements were noted in the symptom score (-0.53 (95%CI, 
-0.92- -0.14; p<0.0001)) (figure 17), emotional function score (-0.523 (95% CI, -0.84- -
0.20; p <0.0001)) (figure 18), and activity limitation score (-0.55 (95%CI, -0.918- -0.18; 
p=0.004)) (figure 19). 
 
No clinically significant changes to vital signs or physical examination parameters were 
observed following the treatment periods. Reported adverse events such as cough, sore 
throat were mainly mild in intensity and all considered to be unrelated or of unlikely 
relationship to the study medication. There were no serious or severe adverse events, nor 
were there any deaths. 
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Comparison of the change in the total Paediatric asthma quality of life questionnaire  
(Juniper) scores between the treatment groups - fluticasone plus montelukast (ML), and 
fluticasone and salmeterol with placebo montelukast (SM).  Results from activity 
limitation, emotional and symptoms were combined and are shown at baseline and 3 
monthly follow-up visits (0 – 4) during treatment period of 12 months.   
 
* Significantly greater improvements were noted for the overall PAQLQ score for the ML 
group compared to the SM group (p = 0.003) 
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Comparison of mean symptom scores between two treatment groups - fluticasone and 
montelukast (ML), and fluticasone and salmeterol with placebo montelukast (SM). 
Paediatric asthma quality of life questionnaire (Juniper) scores for the week preceding 
each visit were obtained at baseline and 3 monthly follow-up visits (0 – 4) during 
treatment period of 12 months. 
 
Error bars represent 95% confidence intervals and p values are shown for the 
comparison between the two treatment groups through the treatment period.  
 
* Significant differences were observed in the asthma symptom outcomes (p = 0.009) i.e. 
improvements were noted in asthma symptom scores in the ML group compared to SM 
group. 
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Comparison of mean emotional function score between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone and salmeterol with placebo 
montelukast (SM).  Paediatric asthma quality of life questionnaire scores93 for the week 
preceding each visit were obtained at baseline and 3 monthly follow-up visits (0 – 4) 
during treatment period of 12 months. 
 
Error bars represent 95% confidence intervals and  p values are shown for the 
comparison between the two treatment groups through the treatment period.  
 
 
* Significant differences were observed in emotional function outcomes (p < 0.0001) i.e. 
improvements were noted in emotional score in the ML group compared to SM group. 
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Comparison of mean activity limitation scores between two treatment groups - 
fluticasone plus montelukast (ML), and fluticasone with salmeterol and placebo 
montelukast (SM).  Paediatric asthma quality of life questionnaire scores for the week 
preceding each visit were obtained at baseline and 3 monthly follow-up visits (0 – 4) 
during trial period of 12 months. 
 
Error bars represent 95% confidence intervals and p values are shown for the 
comparison between the two treatment groups through the treatment period.  
 
* Significant differences were observed in activity limitation score (p < 0.0001) i.e. 
improvements were noted in activity limitation scores in the ML group compared to SM 
group. 
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No significant difference was observed in the exhaled nitric oxide between the treatment 
groups over the study period (data not shown). No clinically significant changes to vital 
signs or physical examination parameters were observed following the treatment periods. 
The treatment-emergent adverse events such as cough, sore throat were mainly mild in 
intensity and all considered to be unrelated or of unlikely relationship to the study 
medication. There were no serious or severe adverse events, nor were there any deaths 
during the study period. 
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SECTION 5 - DISCUSSION 
 
Chapter 15    
 
MAIN FINDINGS 
 
This study was the first prospective randomised control trial in children with asthma 
using previously obtained genotype information relating to β2 adrenergic receptor gene.  
The β2 adrenergic receptor gene has been shown to have an important role in the 
mechanism of one of the most commonly used asthma treatments - β2 agonists. 
 
The study raised a number of ethics-related and nursing issues that merit further analysis 
and discussion. For example, the process of using genotype for randomisation was 
intensely discussed by Ethics committees, and the trial raised a number of interesting 
ethics-related and nursing management-related issues during my interaction with parents, 
children, general practitioners and nursing colleagues. 
 
Hence, my discussion will follow three specific themes. In the first of my chapters, I will 
briefly review the pharmacology-related findings and discuss the genotype-related issues 
underlying the trial findings. In the second chapter, I will reflect on the ethics and 
nursing-related issues that have emerged from my work. The third chapter will reflect on 
the problems that I encountered, how these problems might have been managed more 
effectively, and what I have learnt from the process that will influence my future work. 
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Chapter 16 
 
PHARMACOGENETIC FINDINGS 
 
Overall summary 
The study has shown that asthmatic children with the Arg/Arg 16 genotype appear to 
have better asthma control when prescribed montelukast compared to salmeterol, when 
added to inhaled corticosteroid, over a 12 month period.86  This was apparent within the 
first three months of the study and persisted throughout the year long trial period.  This 
information could support personalised approached medicine prescriptions in the future 
of children’s asthma based on β2 adrenergic receptor genotype. 
 
Variability in treatment response between individuals can be influenced by many factors, 
including concordance. Genetics may contribute to as much as 80% of the variation.85  
The findings of this study support a genetic component i.e. β2AR.  The Arg/Arg 16 
genotype appears to have an important role in determining how well children with asthma 
respond to the treatments most widely used at step 3 asthma guidelines.   
 
Knowledge of the β2AR genotype of a child attending asthma clinics could in the future 
influence treatment decisions, potentially resulting in quicker control of symptoms and 
maximising therapeutic benefit as well as reducing possible side effects.  This could also 
result in positive financial savings. 
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The study was powered showing an n of 30 participants in each arm to provide 80% 
power to detect a significant difference for school absences between the two groups.   
Whilst it must be acknowledged that there are limitations in terms of sample size for the 
study, the findings have implications for future research into the field of 
pharmacogenetics in asthma. 
 
Comparison with findings from other similar published work 
A recent study by Lemanske et al87 did not find any differences in medication response 
according to Arg/Gly variation. They considered genetic differences at the end of a trial 
designed to assess the frequency of differential responses to three blinded step-up 
treatments in children who had uncontrolled asthma while receiving low dose inhaled 
corticosteroids. As part of recruitment criteria asthmatic children were required to show 
reversibility to inhaled beta-agonists, which could be biasing towards participants 
responding to salmeterol.  This has been the case in some adult pharmacogenetic studies, 
Bleecker et al72 and the LARGE study73 also required participants to be responsive to 
short acting beta agonists to be included in the study.   
 
Choice of end point 
School absence is a relevant primary outcome measure for a study involving children.  It 
is easy to measure and relates directly to quality of life in children and is an outcome 
measure that children and their families can relate to.  The choice of endpoint and study 
design are of potential importance in pharmacogenetics studies e.g. using beta agonist 
reversibility as entry requirement in an asthma pharmacogenetc study could be seen to 
bias results in favour of beta agonist responders.   
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Differences in child and adult physiology 
Although the underlying pathophysiology of childhood and adult asthma may be similar, 
effects on growth and development, and the adverse effects of asthma treatments differ. 
Differences such as eosinophil response and specific risks associated with maternal 
smoking88 suggest that the clinical effects of the Arg/Gly variation could differ between 
asthmatic children and adults. Indeed, the effect of the Arg/Gly polymorphic variation on 
inhaled β2-agonist response seems more consistent in children in comparison to adults 
with asthma.27,63  Differences such as this highlight why it is not acceptable to transfer 
results from studies of asthma in adults to paediatric populations 
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Chapter 17 
 
ETHICAL ISSUES AND NURSING RELATED ISSUES 
 
Ethical issues from a nursing perspective 
This chapter presents below a critical analysis of the methodology and design underlying 
the genotype-stratified randomised controlled trial, from a nursing perspective. The 
nursing experience around the process of recruitment for this study forms the basis for 
my key observations around the ethical issues and nursing issues encountered during this 
study. I have primarily focussed on my interaction with children and their families. 
 
Clinical Trials involving children 
The ethics of research with children should be based on careful assessment of potential 
benefits and risks.89 Research nurses play a key role in interpreting guidelines from 
regulatory authorities and child health organisations produced to safeguard the interests 
of children participating in research.90,91  US and EU regulations on paediatric medicines 
positively support that children should be able to benefit from research in clinical 
settings.93,94  Thus to translate advances in pharmacogenetics to benefit children, it is 
necessary to perform studies with child participants that involve genetic screening.  
 
Risk Assessment for child and young adult participants 
The participants were carefully monitored by a specialised paediatric asthma nurse and 
doctor, and the study did not involve any unpleasant tests, therefore presented no major 
increase in risk to the child participants.93 Indeed, the BREATHE observational study63 
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identified this patient sub-group at potential overall risk; however, benefits from 
montelukast or salmeterol could vary in individual cases and genotype-based prescribing 
may not necessarily be of therapeutic advantage. The study therefore was a natural 
progression of clinical planning in terms of nursing practice, keeping in mind the best 
interests of the patient 
 
Prospective Genotyping for child participants 
The study involving both child and adolescent participants and the inclusion of a form of 
genetic testing raised a number of ethical issues that were addressed over the course of 
this study. While there is considerable literature related to the genetic testing of children, 
both for childhood and later onset adult conditions, there has been very little discussion 
of the ethics of pharmacogenetic research on children.94 The work that has been done in 
this area highlights the complex issues around informed consent to such trials (from both 
children and their parents), the limitations on risks that can be taken with children, and 
the complicated genetics involved in cases where genes may be expressed differently in 
children compared to adults.95   
 
Time was taken with discussion of the Arg16 genotype with parents and children prior to 
recruitment. It was explained that the ‘mouthwash study' 63  had identified a specific gene 
about which we were trying to find out more and that when we had looked back we found 
that the children who had a particular genotype had more symptoms. The current 
proposed study was trying to find out more about how the child carrying the risk 
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genotype reacted to the medicines in question, and whether salmeterol (“asthma inhaler”) 
or montelukast (“asthma tablet”) was a better option for treatment in these children. 
 
Clarification of Gene’s Role   
It was important to consider whether parents/children would have prior perceptions about 
genetic testing.  They may have had concerns about the gene being tested for, its role in 
the pharmacogenetics of beta agonists, and even if this would have a long term effect on 
their childs condition.96   In this study, pharmacogenetic testing for the Arg/Arg 16 did 
not raise this ethical issue because the gene appears to relate only to treatment response.97  
One parent did express concerns of a legal nature relating to perceived disclosure 
obligations of genetic testing results to insurers for their child in the future and requested 
to have the child’s information withdrawn from the original pilot database. 
 
Informed consent to genetic testing 
The issue of obtaining informed consent was an ethical issue to consider. While there 
have been very few studies on participant’s attitude towards and understanding of 
informed consent forms in pharmacogenetic trials, what work has been done, and broader 
work on the problems of informed consent should raise questions about how well 
participants understand what it is they are consenting to, when they allow their DNA to 
be sampled.97,98  Whilst I was not involved in initial BREATHE study to obtain a saliva 
sample, it was important that I had an understanding of questions that may arise when 
families where contacted to participate in a second study.  Overall, participants and their 
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parents were interested in contributing to the understanding of the gene-environment 
interactions in childhood asthma and allergy.  
 
Informed consent to enter the study 
Parents were motivated to consent to their children entering the study because there was a 
possible perceived benefit for their own child found to carry the genotype, but also the 
satisfaction of knowing they may be helping other children with asthma in the future.  
Consent was also obtained from the children. A paediatric nurse or a doctor performed 
the consenting and discussed the trial with the carers and the children. It was important to 
take time to always include the children in the consent process. Prior to beginning 
recruitment, the research team worked closely with the Ethics Committee to develop 
child friendly study information leaflets and a consent form where both the children and 
parents were involved in the consent process. The study medicines – inhaled salmeterol 
and oral montelukast - are already widely prescribed in children and young adults with 
asthma, so it was reassuring for parents and children that they were not being asked to 
participate in a study of a novel asthma treatment.  It was important to explain fully to the 
parents that our objective was to test the hypothesis that children and young adults with 
asthma who have the Arg/Arg-16 polymorphic variation will be better controlled by the 
use of montelukast instead of long acting beta2 agonists as controller medication, but that 
this was still an open question. 
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Randomisation procedure 
The parents and young participants also needed to be aware that allocation to a treatment 
group was determined by a randomisation procedure. From an understanding of the 
hypothesis they may have naturally wanted their child to be in the montelukast treatment 
group. In one particular instance, the mother said at the time of randomisation that the 
asthma symptoms of her child, who was found to be carrying the Arg/Arg homozygous 
genotype, had previously responded well to montelukast. This child was randomised to 
the active salmeterol /placebo montelukast arm.  He experienced increased symptoms and 
exacerbations during the initial study period, and eventually decided to withdraw after 6 
months. This was the focus of further discussion regarding ethical and other issues 
surrounding randomisation on the basis of genotype where the available genotypic 
evidence together with the report of clinical response at the start of randomisation could 
have suggested the outcome. 
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Chapter 18 
 
PRACTICAL PROBLEMS AND THEIR MANAGEMENT 
 
The study was an important learning experience and it will influence my views regarding 
the design of randomised controlled trials and other studies in the future. I will 
summarise specific issues of interest and describe how these issues presented in the first 
instance and how they were managed, and difficulties I encountered in the process. 
• Difficulties with recruitment 
• Feedback and response from parents and children 
• Feedback and response from general practitioners and hospital colleagues 
 
Difficulties in Recruitment of appropriate number of participants 
Each child/family identified as carrying the Arg/Arg 16 genotype was systematically 
approached by sending information by post and contacting the families a short time later 
to offer them an appointment to discuss the information further.  Ethics committees 
stipulate that in a trail situation families are given opportunity to read information 
regarding the study so that they are as informed as possible prior to being contacted to 
ask if they would like to consider taking part in the proposed research.   
 
A period of one year had been agreed with the ethics committee during which 
participants could be recruited.  The majority of participants were recruited within the 
first 3 months of the trial.  However after a period we had contacted all potential recruits 
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from the original Arg/Arg genotype list and had not reached the predetermined target 
number - 60.  To be able to detect this difference in effect with a probability (power) 30 
subjects in each group was target number of participants.  However, if each group had 
40-50 participants, the null hypothesis could be disproved with confidence 
 
Actions to increase potential recruitment  
Contact some families previously ineligible 
We decided to contact some of the families who had previously expressed interest in 
participating, for a second time.  These potential participants may not have met entry 
criteria e.g. had experienced no exacerbations the previous year or were no longer 
prescribed inhaled steroids.  It may have been that over the winter months they had 
experienced some asthma symptoms which would then make them eligible to participate.  
Only one further participant kindly agreed to join the study after being contacted a second 
time. 
 
Further laboratory analysis 
At laboratory level Scientists rechecked samples and analysed more recent mouthwash 
samples in order to identify more children with Arg Arg 16 genotype not on the original 
list who could be approached to participate. 
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Consider second recruitment centre – Dumfries 
By May 2008 – 9 months into the study all children identified with Arg/Arg 16 genotype 
(148 children) had been approached and 49 participants had been recruited.  With no 
further potential participants in Tayside, the research team began to consider the 
possibility of extending recruitment area to a second Scottish centre - Dumfries.  Children 
carrying Arg/Arg 16 genotype had already been identified in Dumfries and Galloway 
from the same genetic study used in Tayside. 
 
We contacted our Ethics Committee to discuss the feasibility of adding a second centre to 
the study.  However it quickly became evident that this would involve a long process of 
reapplying to Ethics committee in Dumfries, NHS Research and Development 
departments and MHRA once again.  Effectively restarting the pre-trial process again 
would prolong the study considerably.  It is advisable to apply at the initial stages of pre-
trial procedures if the study is a multi-centre one.  The possible need to use another area 
in Scotland had not been anticipated during our pre-trial work.   
 
We were fortunate to finally recruit 62 children and young adults which was within our 
pre-determined sample size.  The final participants were recruited from the further saliva 
sample analysis results. 
 
Work with General Practise Colleagues 
It was extremely important to have the support of our colleagues in General Practise to 
carry out the study.  An information leaflet clearly explaining what the study involved 
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was sent to each child’s General Practitioner (GP).  A request was also issued to the GP 
to ask them prescribe the accuhaler device with either seretide or fluticasone.  
Montelukast was supplied from our clinical trials pharmacy.  Financial constraints and 
operational difficulties meant, in contrast to montelukast where patients were given 
montelukast or placebo, we were unable to provide blinded accuhaler devices.  We were 
therefore reliant on GP’s to prescribe the accuhaler device.  This request could potentially 
have occurred as a result of a visit to a routine asthma clinic review.  One GP was 
initially reluctant to prescribe the different treatment but he did agree after a meeting with 
the young participant to establish her willingness to participate and some further 
discussion with the research team regarding the study. 
 
Failure to register with Clinical Trials 
ClinicalTrials.gov is a database register of clinical trial details and results of clinical 
studies of human participants conducted around the world.  It is a web-based resource 
where patients, family members, health care professionals, researchers, and the public 
can access information on publicly and privately supported clinical studies on a wide 
range of diseases and conditions. The Web site is maintained by the National Library of 
Medicine (NLM) at the National Institutes of Health (NIH).https://clinicaltrials.gov.  
Unfortunately members of the trial research team were unaware of this site and midway 
through the trial we received communication that it was obligatory to register the trial 
with this site.   
  
The procedure for pre-trial clinical trials has changed considerably since application 
process for this trial.  There is now an Integrated Research Application System and a flow 
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chart to guide researchers through the process.  The Ethics committee now appoint a 
representative from their department to work closely with research teams throughout the 
whole process – pre-trial procedures, trial period and completion of trials.  Therefore 
failing to register with the Clinical trial website should not occur in the future. 
 
Critique of the study 
The following is a short critique of the study design and points that have been raised that 
could be useful in future work. 
  
No control group 
One of the criticisms that could be made about the study design is that there was no 
control group included.  This was a pilot study where the primary hypothesis was that 
children with asthma carrying the Arg/Arg-16 genotype have fewer school absences over 
a period of 1 year on oral montelukast in comparison to inhaled salmeterol.  Our work 
focused on the primary question and for this there was no requirement for having a 
control group. 
 
Blinding 
Children could easily determine which treatment group they had been randomised into 
once they received their accuhaler inhaler device.  As much as could be determined from 
dose counter readings on the device and the numbers of montelukast/placebo tablets 
returned, it did not appear that the knowledge of treatments differed between each 
treatment group. 
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Chapter 19 
 
CONCLUSION 
 
I was very fortunate to be involved in one of the first prospective randomised controlled 
studies involving children with asthma that addresses the hypothesis that asthma 
treatments in the future could be tailored on an individual basis with information about 
genotype. 
 
Concluding remarks on discussion  
I have presented the results of a prospective randomised controlled trial comparing 
second line treatment options in children with asthma who carry the Arg16/Arg16 beta2 
adrenoreceptor genotype.  Although with considerable variability in findings between 
studies, the presence of this genotype has previously been shown to potentially modulate 
short acting beta agonist and/or long acting beta agonist responsiveness. The results of 
the study support the need for a larger blinded study with an appropriate control group.   
 
I have also tried to explore the ethical and recruitment-related issues around the design of 
genotype-stratified randomised controlled trials in children and have discussed some of 
the practical aspects of the ethics-related issues associated with the study, the response of 
parents and children to such issues, and how these issues were managed within the 
context of this study. I hope this provides a platform for further discussion on the 
methodology of prospective genotype-stratified trials in children, particularly from the 
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nursing perspective, as such trials, with varying levels of nurse-researcher involvement, 
are likely to become more relevant to the progress in therapeutics in the future. 
 
Nurse researchers are increasingly involved in the design and conduct of successful 
paediatric clinical trials and are often directly involved in clinical trials recruiting 
children with asthma that aim to answer specific questions of clinical importance. If 
treatments can be designed to meet the specific needs of children with Arg-16 
polymorphic variation, studies such as this require to be performed specifically in 
children. Such work could lead to increased efficacy and response to treatment, and the 
avoidance of adverse effects in childhood asthma therapy. 
 
Why was this research needed? 
• Research papers using observational design, studying children with asthma, 
suggest that response to asthma medication in children may be influenced by 
genotype. 
• There is limited research on the ethical issues around genotyping for randomised 
controlled trials and other research studies particularly in children.  
 
What are the key findings 
• The study explores the practical aspects of ethics-related issues associated with 
such genotyping, within the context of randomisation for studies in childhood 
asthma. 
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• The work considers the response of parents and children in relation to these 
issues, and tries to provide solutions for these issues within the context of this 
research work. 
 
How should the findings be used to influence policy, practice, research and education  
• This could contribute to clinical practice, as genetic testing may improve 
treatment efficacy and minimise risk to children with asthma using β2-agonist 
relievers and other medication.  
• The study should provide guidance for the design of similar trials, for example, 
through the presentation of relevant clinical scenarios that may be encountered 
by the researchers.  
• I have presented the pharmacological findings from the study that are of great 
interest in the treatment of asthma in children, and will be valuable as the field of 
pharmacogenetics in children progresses.   
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